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1. Introduction 
1.1 MicroRNA 
1.1.1 MicroRNA biogenesis and functions 
MicroRNAs (miRNAs) are a class of highly conserved small noncoding RNA with about 22 
nucleotides.1 Until now, more than 1700 mature miRNAs have been identified in human. The 
family of miRNA constitutes about 1-3% of the human genome. Most miRNA genes are 
situated within the intergenic regions and have their own transcription units. About a quarter 
are located within exons or introns of other coding genes where their transcription is 
controlled by the host genes. MiRNAs can be transcribed as monocistronic transcripts or in 
polycistronic clusters, the latter involve several miRNAs situated on a single transcript being 
controlled by the same promoter.2 
The bulk of miRNAs are generated through the canonical pathway of miRNA biogenesis 
(Figure 1.1).1, 3 In the nucleus, miRNA genes are transcribed as primary miRNAs 
(pri-miRNAs) by RNA polymerase II or III (RNA pol II or RNA pol III). For most 
mammalian miRNAs, pri-miRNAs folds into a hairpin structure characteristic of miRNA 
genes. The hairpin is recognized and cleaved to precursor miRNAs (pre-miRNAs) of about 
50-150 nucleotides by by Drosha (an RNase III enzyme) and Dgcr8 (a crucial cofactor of 
Drosha) in the nucleus. The pre-miRNAs are then exported to the cytoplasm by a nuclear 
RNA-export factor exportin 5. In the cytoplasm, this is further excised to a short 
double-stranded RNA duplex by an RNAse III enzyme, Dicer. The miRNA duplex later 
separates into single-stranded mature miRNA, and incorporates into the RNA-induced 
silencing complex (RISC), which is composed of Argonaute proteins. Partial complementarity 
results in translational repression, while complete complementarity triggers mRNA 
degradation. 
The interaction between miRNA and mRNA mainly depends on the seed sequence of 
miRNA (2-8 nt of 5' terminal).4 Beside this region, the 3' terminal region are not essential but 
may compensate for weaker seed interaction. MiRNAs are post-transcriptional regulators, as 
they negatively regulate protein translation by a mechanism that depends on the 
complementarity between the miRNA and target messenger RNA. Moreover, there is also 
evidence that miRNAs regulate mRNA expression in alternative. As previous work revealed, 
some miRNAs can target the coding regions or the 5′-UTR to regulate gene expression 
whereas others can positively activate the translation of mRNA.5, 6 
As the function of miRNA mainly depends on its seed sequence, target prediction databases 
(including TargetScan, miRanda and Pictar) are predicted that a single miRNA may 
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simultaneously target more than 100 mRNAs.1, 7, 8 In contrast, a single mRNA could also be 
regulated by many miRNAs. Human miRNAs are potential to control the activity of 30-60% 
of all protein-coding genes. Thus, miRNAs are integrated into vast regulatory networks and 
participate in the regulation of diverse biological processes, such as proliferation, 
differentiation, apoptosis, immune response, and viral replication.1, 9, 10 
Moreover, miRNAs could be considered as a possible form of intercellular communication 
in many diseases, including atherosclerosis, Parkinson’s disease, fatty liver, and cancer.11-17 As 
miRNAs are stable in plasma, plasma miRNAs are potential as novel biomarkers.18, 19  
 
Figure 1.1 MicroRNA biogenesis 
In the nucleus, miRNAs are transcribed as either monocistronic or polycistronic pri-miRNAs by Pol II. 
Pri-miRNAs cleaved by Drosha and Pasha to pre-miRNAs are exported to the cytoplasm by exportin 5. In the 
cytoplasm, pre-miRNAs are excised to double-stranded miRNA: miRNA* duplex of 20-23 nucleotides by Dicer. 
The miRNA duplex unwinds to single-stranded mature miRNA, and incorporates into RNA-induced silencing 
complex (RISC), which is composed of Argonaute proteins. The miRNA/RISC complex binds to the 
3′-untranslated region (3′-UTR) of target cellular gene and negatively regulates gene expression with a 
mechanism depending on the complementarity between miRNA and its target mRNA. Perfect complementarity 
triggers mRNA degradation, while partial complementarity results in translational repression.3 
 
1.1.2 MiRNA and HBV 
miRNAs can modulate hepatitis B virus (HBV) replication through directly and indirectly 
affecting its transcription.20-24 To date, some cellular miRNAs have been shown to modulate 
HBV transcription through regulating cellular factors, such as transcription factors and 
nuclear receptors, at the transcription level (Figure 1.2).25-27 Our previous work showed that 
miR-1 and -449a overexpression by an epigenetic mechanism resulted in a marked increase in 
nuclear receptor farnesoid X receptor alpha (FXRα) expression, leading to enhanced activity 
of the HBV core promoter and subsequently HBV replication.23, 28 MiR-372 and -373 are able 
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to promote HBV gene expression via a pathway involving nuclear factor I/B.29 MiR-122 may 
indirectly act on HBV replication via downregulation of its target cyclin G1, thereby blocking 
the interaction between cyclin G1 and p53 and abrogating p53-mediated inhibition of HBV 
replication.22 In contrast, miR-141 suppresses HBV expression and replication by targeting 
peroxisome proliferator-activated receptor (PPAR)-α.30 Similarly, miRNA-130a targets the 
metabolic regulators PPAR-γ and its co-activator PGC1-α and thereby inhibits HBV 
replication.27  
Alterations in miRNA expression profiles have emerged as important indicator of changes 
in gene expression that either favor or restrict virus replication.31, 32 A set of circulating 
miRNAs are aberrantly expressed in the peripheral blood of chronically HBV-infected 
children and patients.33-35 Among them, miR-125b had increased serum levels in the 
correlation with high HBV loads and was found to enhance HBV replication in a 
dose-dependent manner in vitro.36 Interestingly, another miRNA, miR-99a, was consistently 
found to have elevated serum levels in CHB patients along with miR-122 and -125b, partly 
associated with hepatitis B e antigen (HBeAg) positivity.33-35 
 
Figure 1.2 Cellular miRNAs effect on HBV transcription 
(A) The HBV RNA start site for the major viral transcripts (Pre/core, PreS1, PreS, and X), and viral enhancer I 
and II are schematically depicted as boxes. DR I and DR II are two short repeats essential for viral replication. 
Two androgen response elements which are located at enhancer I region are represented as ARE. The miRNAs 
targeting cellular factors edentified for modulating HBV transcription and host cellular transcription factors 
binding to HBV genome are shown. (B) Positions of binding sequences in HBV transcripts proposed to be 
targeted by miRNAs are shown. MiRNAs which were predicted to probably bind HBV transcripts by four well 
established target-prediction software are represented as italic gray color.20 
Besides host cellular miRNAs involving in regulating viral replication, a few viruses could 
also encode miRNAs to benefit its survival. For example, miRNAs encoded by herpes 
simplex virus appear to promote viral latency by inhibiting viral lytic replication. Further data 
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indicate that the consequences may be mediated by direct targeting of key viral replication 
genes or by modulating host relative factors.31, 37 
Furthermore, virus infection can also change the miRNA expression profile.25, 26, 33 Winther 
et al. found there were differential plasma miRNA profiles in HBeAg positive and HBeAg 
negative children with chronic hepatitis B.33 Moreover, it was described that HBx 
significantly up-regulated the levels of 7 miRNA expression, but down-regulates the levels of 
11 miRNA expression, respectively. However, an inverse correlation was noted between the 
expression of HBx and that of the highly-expressed members of the let-7 family, including 
let-7a, let-7b and let-7c, in HCC patients.38 Addtionally, HBV may explored some strategies 
to prevent infected cells from undergoing apoptosis and to escape from the immune responses 
in host cells through affecting the miRNA expression profile.39 
 
1.2 Hepatitis B virus 
1.2.1 Molecular structure 
HBV is an enveloped double stranded DNA virus and belongs to the hepadnavirus family.40 
HBV consists of three kinds of particle forms, Dane particle, filaments and spheres (Figure 
1.3). The mature virons (named Dane particle) are with a virion diameter of 42 nm. The viral 
particle consists of an outer lipid envelope and an icosahedral nucleocapsid core composed of 
protein. The nucleocapsid encloses the viral DNA and a DNA polymerase that has reverse 
transcriptase activity similar to retroviruses.41 The outer envelope contains embedded proteins 
which are involved in viral binding and entry into susceptible cells. Besides the Dane particle, 
the subviral particles, including filaments and spheres, are pleomorphic and exised in patient 
serum, including filamentous and spherical bodies These two particles are not infectious and 
are composed of the lipid and protein that forms part of the surface of the virion, which is 
called the surface antigen (HBsAg), and is produced in excess during the life cycle of the 
virus.42 
With about 3.2 kb genome, HBV is known as one of the smallest DNA virus.43 HBV 
genome consists of four overlapping open reading frames encoding the multifunctional 
polymerase/reverse transcriptase (RT), the capsid-forming core protein, the three closely 
related envelope proteins, and the regulatory X protein. The HBV genome is partially double 
stranded, relaxed circular DNA represented by the bold inner circles. The rcDNA is converted 
to cccDNA, which serves as the template for transcription of the HBV RNA (3.5, 2.4, 2.1 and 
0.7 kb). Pregenomic RNA (pgRNA) is selectively packaged inside core particles, followed by 
P protein-mediated (-) strand DNA synthesis, pgRNA degradation, and (+) strand DNA 
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synthesis to generate rcDNA. These RNAs are exported to cytoplasm for protein translation. 
Multiple transcripts are employed to express the seven viral proteins.  
 
 
Figure 1.3 Schematic model of hepatitis B virus 
(A) Virions and (B) subviral particles. The virion contains a partially double-stranded DNA genome, still 
associated with the viral polymerase (Pol) and encapsidated by 120 core-protein dimers. The core is enveloped 
by three viral surface proteins-the large (LHBs), middle (MHBs), and small (SHBs) proteins (shown as dimers) 
that are cocarboxyterminal and differ by protein length and glycosylation. The subviral particles (filaments and 
22-nm spheres) do not contain a nucleocapsid and differ by their amount of LHBs.40 
 
 
Figure 1.4 Genome organization of HBV 
Genetic organization of the HBV genome and mechanisms of viral protein translation. Shown innermost is the P 
(polymerase) open reading frame (ORF) overlapping completely with the preS1/preS2/S ORF, and partially with 
preC/C ORF and X ORF. Next are partially double stranded DNA genome found inside virions, with the (-) 
strand DNA having the P protein attached to its 50 end and the (+) strand DNA having incomplete 30 end 
(dashed line). The two direct repeat (DR) sequences, DR1 and DR2, are critical for HBV DNA replication and 
genome circularization. The outmost are four classes of HBV RNAs transcribed from the cccDNA template: 0.7 
kb X mRNA (for HBx protein), 2.1 kb S mRNA (for M and S proteins), 2.4 kb preS mRNA (for L protein), and 
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3.5 kb pgRNA (for core and P proteins). In addition, the 3.5 kb precore RNA (not shown) is used for HBeAg 
expression.43 
 
1.2.2 Life cycle 
HBV is one of a few known non-retroviral viruses which use reverse transcription as a part of 
its replication process.40, 43 Thus, the viral life cycle is special and complicated (Figure 1.5).  
Attachment: HBV can target the cells by binding to a receptor on the surface of the cell 
and enters it by endocytosis. Na+-taurocholate cotransporting polypeptide (NTCP) has been 
found and recognized as a specific receptor of HBV.44, 45 The early steps of HBV virion 
infecting hepatocytes are specific and probably irreversible binding to hepatocyte-specific 
preS1-receptor. This step presumably requires activation of the virus resulting in exposure of 
the myristoylated N-terminus of the L-protein.46 The step of HBV entry are though two 
different entry pathways: one is endocytosis followed by release of nucleocapsids from 
endocytic vesicles; the other is fusion of the viral envelope at the plasma membrane.47  
Penetration: The virus membrane then fuses with the host cell membrane releasing the 
DNA and core proteins into the cytoplasm.47  
Uncoating: The nucleocapsid in cytoplasm could be transported along microtubules into 
nuclear.48 Then, the partially double stranded viral DNA is dissociated from the core proteins 
and released into the nucleoplasm. The DNA is repaired to fully double stranded and 
transformed into covalently closed circular DNA (cccDNA) that serves as a template for 
transcription of four viral mRNAs.49, 50  
Replication: The largest transcript pgRNA is used to make the new copies of the genome 
and to make the capsid core protein and the viral DNA polymerase. In the nucleus, rcDNA 
could be repaired and form cccDNA by viral polymerase, combined with host cellular 
enzymes.51 The cccDNA serves as a transcriptional template in the nucleus and utilizes the 
cellular transcriptional machinery to produce all viral RNAs.49 The RNA transcripts are then 
transported to the cytoplasm and translate into associated proteins, while pgRNA is assembled 
with core protein and polymerase proteins to form the RNA-containing nucleocapsid in 
cytoplasm. Maturation of RNA-containing nucleocapsid, including synthesis of the (-) DNA 
strand, pgRNA degradation and synthesis of the (+) DNA strand by the different enzyme 
activities of viral polymerase.52 
Assembly: Four viral transcripts, including 3.5 kb preC RNA and pgRNA, 2.4 and 2.1 kb 
preS/S mRNAs, and 0.7 kb HBx, undergo additional processing and go on to form progeny 
virions. The long mRNA is then transported back to the cytoplasm where the virion P protein 
synthesizes DNA via its reverse transcriptase activity.53, 54 
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Release: Nucleocapsids can be directly bud into the endoplasmic reticulum (ER) or 
proximal Golgi membranes to acquire their glycoprotein envelope to trigger new virions 
secretion, or they are re-imported to nucleus to amplify the cccDNA pool.55 This pathway is 
important for virus persistence in hepatocytes and also contributes to the relapse of viremia 
after stopping antiviral treatment in chronic HBV infected patients.49 
 
Figure 1.5 HBV life cycle 
HBV enters hepatocytes through the specific receptor Na+-taurocholate cotransporting polypeptide (NTCP), 
followed by uncoating, and nuclear transport of the rcDNA. The rcDNA is converted to cccDNA, which serves 
as the template for transcription of HBV mRNA. These RNAs are exported to cytoplasm for protein translation. 
pgRNA is selectively packaged inside core particles, followed by P protein-mediated (-) strand DNA synthesis 
(reverse transcription), pgRNA degradation, and (+) strand DNA synthesis to generate rcDNA. Mature core 
particles are enveloped for release as virions, or transported to the nucleus to generate more cccDNA.43 
 
1.2.3 HBV-associated liver diseases 
Until now, HBV infection is still one of the most common chronic viral infection in the world. 
Over 248 million individuals are carriers with HBsAg worldwide.56 Normal people can be got 
HBV infection through contact with infected blood and semen, then led to acute or chronic 
infection. Acute HBV infection is self-limiting and may be self-cleaned in several months. 
However, chronic HBV infection is associated with an elevated risk of developing hepatitis, 
liver cirrhosis, and hepatocellular carcinoma (HCC).47 Overall, as much as 40% of men and 
15% of women with perinatally acquired HBV infection will die of liver cirrhosis or HCC.57 
Currently, HCC is ranks the third leading cause of cancer-related deaths worldwide.58 The 
liver tumor, which arises from hepatocytes, is often associated with liver cirrhosis resulting 
from chronic liver diseases. Among the environmental risk factors, the prevalence of chronic 
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hepatitis B and C virus infections is linked directly to the incidence of HCC. It is well known 
that the HBV DNA genome is able to integrate into the cellular chromosomal DNA, causing 
host genome rearrangements and enhancing the instability of the host chromosome, leading to 
large inverted duplications, deletions and chromosomal translocations.59 So far, chronic and 
persistent infection with HBV is a major risk factor for the development of HCC. 
Approximately 25% of chronically HBV-infected individuals will develop HCC.60 Chronic 
carriers of HBV have up to a 30-fold increased risk of HCC.61 In areas of high HBV 
endemicity, persons with cirrhosis have an approximately 16-fold higher risk of HCC than the 
inactive carriers, and a 3-fold higher risk for HCC than those with chronic hepatitis but 
without cirrhosis.62 Although the mechanisms of oncogenesis of HBV remain obscure, several 
factors have been identified to be associated with a high risk of developing HCC among 
chronic hepatitis B (CHB) patients. Such as HBx, which is not binding directly to DNA, but 
rather acts on cellular promoters by protein-protein interactions and by modulating 
cytoplasmic signaling pathways, appears to play a critical role in the development of 
HCC.63-66 HBV exerts its oncogenic potential through a multi-factorial process, which 
includes both indirect and direct mechanisms that likely act synergistically.67 Moreover, the 
association between HCC and HBV recurrence after liver transplantation, and the detection of 
cccDNA in HCC cells points toward the possibility of HBV replication in tumor cells. The 
latter could act as potential reservoirs for HBV recurrence, especially in patients who present 
with a recurrence of HCC.68 
Since the preventive vaccine was available in 1981, the implementation of universal 
vaccination in infants has played a critical role in the sharply declined prevalence.57 Several 
erological markers of HBV infection, including HBsAg and anti-HBs, HBeAg and anti-HBe, 
and anti-HBc IgM and IgG, have being used in clinical diagnosis. Currently, the treatments for 
patients with chronic HBV infection include interferon-α and nucleoside analogues, however, 
they are limited by low rates of sustained response, side effects, and the emergence of drug 
resistance.69 The key obstacle against curing chronic hepatitis B is the inability to eradicate or 
inactivate cccDNA.49, 70 Thus, it is urgent to understand HBV-host interactions at the 
molecular level and to identify novel molecular targets for HBV therapy. 
 
1.2.4 Modulation of HBV replication 
HBV replication is regulated by many extracellular and intracellular factors, such as specific 
hormones, inflammatory cytokines, intracellular signaling pathways, and metabolic 
processes.71-74 HBV gene expression can be modulated both in transcriptional or 
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posttranscriptional process.  
The HBV cccDNA plays a key role in the viral life cycle and permits the persistence of 
infection.49 cccDNA accumulates in hepatocyte nuclei and forms a stable minichromosome 
organized as a template for the transcription of viral mRNAs. Thus, HBV utilizes the cellular 
transcriptional machinery to produce all viral RNAs necessary for viral protein production 
and viral replication.75, 76 Moreover, the acetylation status of cccDNA-bound histones is 
closely correlated with viremia levels, indicating that epigenetic mechanisms can regulate the 
transcriptional activity of the cccDNA.76 Our previous data demonstrated that the ectopic 
expression of miRNAs, such like miR-1, miR-449a, resulted in a marked increase of HBV 
replication through up-regulated HBV transcription in hepatoma cells.23, 28, 77 
Virus replication also relies on host cells. The ability of HBV replication mainly depends 
on the nature of the antiviral stimulus applied. Host cellular factors participate in HBV life 
cycle in almost every step from cccDNA formation, transcription, core particle formation and 
progeny secretion. The proliferation status of host cell also affect HBV replication.23, 28 In 
addition, HBV replication can be controlled by a variety of cellular transcription factors, in 
particular, several nuclear receptors like farnesoid X receptor a (FXRA), hepatocyte nuclear 
factor 4a (HNF4A), liver X receptor (LXR), retinoid X receptor a (RXRA), and peroxisome 
proliferator activated receptor a/c (PPARA/G).25 
Moreover, there are other cell pathways that contribute to control HBV replication, such as 
host innate immunity.78 As the results shown previously, type I IFNs, proinflammatory 
cytokines, and chemokines play essential roles in controlling HBV infection. IFNs elicit an 
anti-viral response by triggering the JAK-STAT signaling pathway, followed by increasing 
the levels of IFN-stimulated genes (ISGs) expression, whose products exhibit antiviral 
effects.79 At present, activation of innate immune response can act as therapeutic approaches 
for chronic hepatitis B infection. 
Among the relevant intracellular pathways, the phosphatidylinositol 3-kinase (PI3K)/Akt 
signaling pathway is a major cellular pathway involved in regulating HBV infection.80, 81 Guo 
et al. reported that HBV replication could be inhibited by activation of the PI3K/Akt signal 
pathway.80 This mechanism is likely in part responsible for the reduced HBV replication 
observed in tumor cells, which can show activation of the PI3K/Akt pathway. Moreover, 
Hepatitis B surface antigen (HBsAg) synthesis may also be regulated through the 
PI3K/Akt/mTOR signaling pathway.82 
HBV could also be regulated by metabolic processes, including autophagy.83-86 Autophagy 
is also known as one of the host defense responses against infections. However, it has been 
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demonstrated that HBV induces autophagy and elicite this to facilitate its DNA replication. 
This process is mediated by HBx protein, which binds to and activates class III 
phosphatidylinositol-3-kinase (PI3KC3), an enzyme important for autophagy initiation.87, 88 
There is also evidence showing that the small HBV surface protein was required to induce 
autophagy formation by triggering unfolded protein responses.89 
 
1.3 Autophagy 
1.3.1 Autophagy formation 
Macroautophagy (herein named simply as ‘‘autophagy’’), an evolutionarily conserved 
intracellular process, engulfs long-lived cytoplasmic macromolecules and damaged organelles 
and delivers them to lysosomes for degradation and recycling.90 This process is essential for 
maintaining cellular homeostasis in response to multiple stress signals, including nutrient 
starvation, stress and pathological conditions.91 There are two different autophagy pathways: 
one is selective autophagy by removing defective organelles, protein aggregates, cell 
reorganization upon differentiation, and intracellular parasites; the other is non-selective 
autophagy by removing ribosomes, organelles, and cytoplasma during starvation. 
Complete autophagy involves the formation of a double membrane construction, known as 
autophagosome.90, 91 The formation of autophagosomes is arised from a phagophore assembly 
site (PAS). The formation of the phagophore from the PAS requires the subsequent activity of 
the ULK1/2 (Atg1 in yeast) kinase complex and 2 ubiquitin-like conjugation systems, 
including the ATG12–ATG5-ATG16L1 complex and the phosphatidylethanolamine 
-conjugated LC3/Atg8. Next, the autophagosome travels through the cytoplasm to the 
endolysosomal system to form amphisomes or autolysosomes, and then degrade the contents 
(Figure 1.6). Within the lysosomes, the cargo of macromolecules, damaged organelles, and 
viral proteins in the autophagosome are degraded through lysosomal hydrolases.92  
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Figure 1.6 Schematic depiction of autophagy 
Mammalian autophagy consists of the formation of the phagophore, the elongation and expansion of the 
phagophore, closure and completion of a double-membrane autophagosome, autophagosome maturation through 
docking and fusion with an endosome (known as an amphisome) and/or lysosome (known as an autolysosome), 
breakdown and degradation of the autophagosome inner membrane and cargo inside the autolysosome. The core 
molecular machinery has already been depicted. The ULK1 and ULK2 complexes are required for autophagy 
induction; class III PtdIns3K complexes are involved in autophagosome formation; mammalian Atg9 (mAtg9) 
potentially contributes to the delivery of membrane to the forming autophagosome and two conjugation systems, 
the LC3-II and Atg12-Atg5-Atg16L complex.91 
 
1.3.2 Signaling regulation of autophagy 
Autophagy is a complex process and involved in many signals pathway.91 Autophagy is 
initiated by the ULK1 kinase complex and receives signal from mTOR complex.93, 94 Once 
the mTOR kinase activity is inhibited, autophagosome formation occurs. This involves 
PI3kinaseIII which forms a complex with Beclin 1. Human Beclin 1 is the first identified 
mammalian gene to induce autophagy. Autophagosome formation also requires LC cleavage 
and protein conjugation systems that resemble ubiquitin (Atg proteins). LC3 
(microtubule-associated protein 1 light chain 3) is one of the mammalian Atg8 homologues 
and present in two forms: LC3-I (cytosolic form) and LC3-II (membrane-bound form). On 
induction of autophagy, LC3-I was converted to LC3-II. The LC3 system is important for 
transport and maturation of the autophagosome. Once an autophagosome has matured, it fuses 
its external membrane with lysosomes to degrade its cargo. 
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Autophagy is regulated by a complex signalling network of various stimulatory and 
inhibitory inputs (Figure 1.7).91 MTOR plays a central role in autophagy by integrating the 
class I PtdIns3K signalling and amino acid-dependent signalling pathways. In 1995, Meijer’s 
group showed that an inhibitor of mTOR, rapamycin, could induce autophagy in rat 
hepatocytes and relieve the inhibitory effect of amino acids on autophagy.95 They also 
demonstrated that amino acids stimulated the phosphorylation of ribosomal protein S6, an 
effect inhibited by rapamycin, providing a connection between amino acid-dependent and 
mTOR-dependent regulation. The mTOR signalling pathway is critical because of its ability 
to integrate the information from nutrient, metabolic and hormonal signals.96   
Activation of insulin receptors stimulates the class I PtdIns3K complex and small GTPase 
Ras, leading to activation of the PtdIns3K-PKB-mTOR pathway.97 PKB phosphorylates and 
inhibits the tuberous sclerosis complex 1/2 (TSC1-TSC2), leading to the stabilization of Rheb 
GTPase, which in turn activates mTOR, causing inhibition of autophagy. Subsequent studies 
demonstrated that activation of this pathway, by expressing an active form of PKB, or 
expressing a constitutively active form of PDK1, has an inhibitory effect on autophagy. 
Moreover, mTOR is a downstream target: rapamycin reverses the inhibition of autophagy that 
results from activation of the class I PtdIns3K pathway.94, 98  
Energy depletion causes the AMP-activated protein kinase (AMPK) to be phosphorylated 
and activated by LKB1.94 AMPK phosphorylates and activates TSC1-TSC2, leading to 
inactivation of mTOR and autophagy induction. p70S6K kinase is a substrate of mTOR that 
may negatively feed back on mTOR activity, ensuring basal levels of autophagy that are 
important for homeostasis. 
Although mTOR was considered central to autophagy regulation, mTOR-independent 
pathways have been recently reported. Amino acids inhibit the Raf-1-MEK1/2-ERK1/2 
signalling cascade, leading to inhibition of autophagy.97 JNK1 and DAPK phosphorylate and 
disrupt the association of anti-apoptotic proteins, Bcl-2 and Bcl-XL, with Beclin 1, leading to 
the activation of the Beclin 1-associated class III PtdIns3K complex and stimulation of 
autophagy.99, 100  
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Figure 1.7 Signaling regulation of mammalian autophagy 
Autophagy is regulated by a complex signaling network of various stimulatoryand inhibitory inputs. MTOR 
plays a central role in autophagy by integrating the class I PtdIns3K signalling and amino acid-dependent 
signalling pathways. Activation of insulin receptors stimulates the class I PtdIns3K complex and small GTPase 
Ras, leading to activation of the PtdIns3K-PKB-mTOR pathway. PKB phosphorylates and inhibits the 
TSC1-TSC2, leading to the stabilization of Rheb GTPase, which in turn activates mTOR, causing inhibition of 
autophagy. Amino acids inhibit the Raf-1-MEK1/2-ERK1/2 signalling cascade, leading to inhibition of 
autophagy. Energy depletion causes the AMPK to be phosphorylated and activated by LKB1. AMPK 
phosphorylates and activates TSC1-TSC2, leading to inactivation of mTOR and autophagy induction. JNK1 and 
DAPK phosphorylate and disrupt the association of anti-apoptotic proteins, Bcl-2 and Bcl-XL, with Beclin 1, 
leading to the activation of the Beclin 1-associated class III PtdIns3K complex and stimulation of autophagy. 
Beclin 1 is shown bound to the phagophore membrane.91 
 
1.3.3 Autophagy and HBV 
In recent years, some studies have reported that HBV could also be regulated by metabolic 
processes, including autophagy.83-86 Autophagy, an evolutionarily conserved intracellular 
process, engulfs long-lived cytoplasmic macromolecules and damaged organelles and delivers 
them to lysosomes for degradation and recycling.90 Complete autophagic process mainly 
involves the formation of autophagosomes, known as early autophagy, and their fusion with 
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lysosomes and cargo degradation in the lysosomes, known as late autophagy. The cargo of 
autophagosomes will subsequently be degraded by lysosomal enzymes.101 Xie et al. reported 
that activation of PRKAA/AMPK promotes autolysosome-dependent degradation through 
stimulation of cellular ATP levels, which then leads to the depletion of autophagic 
vacuoles.102 
Autophagy has been implicated in a number of cellular and developmental processes, 
including cell-growth control and programmed cell death.91 Notably, the dysfunction of 
autophagy has been implicated in multiple diseases, including neurodegenerative diseases, 
muscle diseases, cancer, cardiac diseases, and infectious diseases. Autophagy can contribute 
to innate and adaptive immunity against intracellular microbial pathogens or their products.103, 
104  
However, this intracellular process can also be exploited by some viruses to benefit their 
replication, such as HBV, HCV, HIV, dengue virus, and influenza A virus.87, 105-108 In recent 
years, HBV has been shown to induce partial autophagy to facilitate its own replication 
(Figure 1.7). Sir et al. reported that the hepatitis B x (HBx) protein interacts with class III 
phosphatidylinositol 3-kinase to enhance autophagosome formation, which in turn activates 
viral DNA replication.87 Moreover, the results of Liu et al. revealed that HBx impaires 
lysosome maturation by inhibiting lysosomal acidification without disturbing 
autophagosome-lysosome fusion, which may be beneficial for HBV replication.109 In addition, 
Li et al. reported that the small HBV surface protein triggers the unfolded protein responses 
and enhances the autophagic process without promoting protein degradation by the lysosomes, 
which is required for HBV envelopment but not for efficient HBV release.89 Thus, cellular 
autophagy is closely related with HBV envelopment or its replication. 
 
Figure 1.8 Autophagy in the life cycle of HBV 
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The HBx RNA directs the synthesis of HBx protein, which activates PI3KC3 to enhance autophagy, which in 
turn activates viral DNA replication. The S RNA codes for the viral surface antigens, which triggers the unfolded 
protein responses and enhances the autophagic process.85 
 
1.4 Rab 
1.4.1 Rab function 
The Rab proteins are small GTPases that act as molecular switches, to control the formation, 
transport, tethering and fusion of vesicles in the secretory and endocytic pathways.110, 111 
More than 70 Rabs have been detected in humans, however, many of their functions remain 
unknown.112 Previous papers revealed that impaired Rab cascades could cause alterations in 
the autophagic process leading to various human diseases. 
All of the Rabs contain a conserved nucleotide binding domain, which is able to bind both 
GTP and GDP.112 Rabs generally cycle between GTP-bound active and GDP-bound inactive 
forms (Figure 1.9). In their active state, Rab proteins recruit various effectors to the 
membrane, which they are attached to. Rabs have a low intrinsic hydrolase activity; their 
hydrolysis rate depends on GTPase-activating proteins (GAPs). These proteins can 
complement the catalytic site of Rabs, thereby promoting GTP hydrolysis. Inactive, 
GDP-bound Rabs are removed from their target membrane and kept soluble in the cytoplasm 
by GDP dissociation inhibitors (GDIs). Upon Rab activation, GDIs are removed mainly by 
GDI displacement factors (GDFs). Thereafter, guanine nucleotide exchange factors (GEFs) 
activate Rab proteins by stimulating the exchange of GDP to GTP. Active Rabs can stably 
attach to membrane surfaces via their C-terminal lipid (geranylgeranyl) anchor, provided by 
Rab escort proteins. 
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Figure 1.9 GTP-GDP exchange cycle of Rab proteins 
Rabs cycle between GTP-bound active and GDP-bound inactive forms. In their active, membrane-attached state 
they recruit various effectors. GTPase-activating proteins (GAPs) increase the GTP hydrolysis rate, thereby 
inactivating Rabs. Inactive Rabs are sequestered in the cytosol by GDP dissociation inhibitors (GDIs). Upon Rab 
activation, GDI displacement factors (GDFs) can displace GDIs. Afterwards, guanine nucleotide exchange 
factors (GEFs) activate Rab proteins by changing GDP to GTP.112 
 
1.4.2 Rab and autophagy 
Rab5 and autophagy 
Rab5 is a well-known marker of early or sorting endosomes (EEs). Active Rab5 recruits 
effector proteins, which play a role in maintaining, trafficking, cargo recycling, and 
maturation of EEs.113 Rab5 is involved in vesicle fusion events through its effectors CORVET 
and EEA1/Vac1. Furthermore, Rab5 participates in the endosomal recruitment of 
PIK3C3/VPS34, which in turn produces phosphatidylinositol 3-phosphate (PtdIns3P) on the 
EE membrane.114 
Moreover, Rab5 was found to be a regulator of the early steps of autophagosome 
formation.111, 113, 115 Similar to its endosomal functions, Rab5 may have a role in the 
recruitment of the autophagic BECN1-PIK3C3 complex and subsequent PtdIns3P production 
on the phagophore membrane.114 Previous work showed that Rab5 regulated the conjugation 
of ATG12 to ATG5 through its effector, PIK3C3, as a part of the autophagic BECN1 
complex.116 This study suggested a direct role for Rab5 in the process of autophagosome 
formation, since its effect on autophagy was not due to its endocytic roles or through the 
regulation of mTOR signaling. Moreover, both Rab5 and PIK3C3 were found to be required 
for the formation of autophagosomes during autophagy induced by the nonstructural protein 
4B (NS4B) of hepatitis C virus.114 Interestingly, recent studies showed that the catalytic 
subunit of the class IA phosphoinositide 3-kinase complex, PIK3CB/p110-β, facilitated the 
function of Rab5, however, loss of PIK3C3 led to impaired autophagy.117  
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Figure 1.10 The functions of Rab proteins in autophagy 
The schematic picture shows the interactions of autophagy with the endocytic and secretory pathways. Series of 
Rab small GTPases play a role in the earliest steps of autophagosome formation by providing various membrane 
sources for the PAS. RAB5 participates in this autophagic stage, through its interactions with the 
PIK3C3-BECN1 complex. Rab7 has both direct roles in the transport of autophagosomes and amphisomes and 
indirect roles in the fusion process of autophagosomes with late endosomes. ER, endoplasmic reticulum; TGN, 
trans-Golgi network; PAS, phagophore assembly site.112 
 
Rab7 and autophagy 
After cargo recycling, EEs mature into late endosomes (LEs).118 During the maturation 
process, inactivated Rab5 is substituted by Rab7 on the endosomal membrane. Subsequently, 
Rab7 recruits its effectors, RILP (Rab-interacting lysosomal protein) and OSBPL1A/ORP1L 
(oxysterol-binding protein-like 1A), which are required for LE trafficking and fusion with 
lysosomes.119  
Similar to its endosomal functions, Rab7 is required for fusion of autophagosomes with late 
endosomes or lysosomes. Previous studies revealed that Rab7 colocalizes with LC3, and 
silencing or overexpression of dominant negative Rab7 leads to an increase in size and 
number of autophagosomes due to impairing their fusion with lysosomes.120, 121 Supporting 
these findings, a recent study revealed a similar role for Rab7 was in selective autophagy.122 
Although some results show that the homotypic fusion and vacuole protein sorting (HOPS) 
complex-associated SNAREs VTI1B and VAMP8 play a role in this fusion process, the 
HOPS member VPS16 was not found to be necessary for it.123 In addition, other RAB7 
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effectors, UVRAG, KIAA0226/Rubicon, and RNF115 have a role in autophagosome 
maturation.119, 124 Furthermore, Rab7 is also described in autophagosome formation through 
the effector PLEKHF1/Phafin1.125 
However, it is possible that these Rab7 effector proteins have an indirect impact on the late 
stages of autophagy.111, 113 There are several lines of evidence that closed autophagosomes 
fuse not only with lysosomes, but also with various populations of endosomes to form hybrid 
organelles called amphisomes. In many cell types amphisome formation seems to be essential 
for subsequent lysosomal fusion and degradation. Thus, in these cells the presence of mature 
endosomes is required for the completion of the autophagic process. Consequently, it is 
possible that impairment of autophagic maturation due to depletion of Rab7 or UVRAG is 
caused in fact by the lack of mature endosomes.118, 119 Supporting this, recent studies showed 
that direct autophagosome-lysosome fusion is mediated independently of Rab7 and its 
effectors, by the SNARE protein STX17 (syntaxin 17).126 All of these studies suggest that 
Rab7 effectors facilitating endosome maturation have a cell typedependent role in autophagy. 
There are only a few studies revealing a role for Rab7 in other stages of autophagy.111, 113 
Rab7 is implicated at the formation of autophagosomes. Recent studies showed that Rab7 is 
required at the initial steps during the antibacterial autophagic response against GAS.127 Their 
data showed that depletion of Rab7 led to a decrease in formation of GAS-containing 
autophagicvacuoles. A former paper indicated that mTOR regulates the process of autophagic 
lysosome reformation likely through Rab7.120  
Collectively, the endosomal Rabs, including Rab5 and Rab7, have important functions in 
autophagy regulation. It is necessary to clarify and investigate the distinct roles of Rab5 and 
Rab7 cascades in orchestrating autophagy. 
 
1.4.3 Rab and HBV 
Previous studies have shown that autophagy can be exploited by HBV to facilitate their 
replication.106, 107, 128, 129 Autophagy was recognized to have a significant impact on HBV 
replication, as well as viral envelopment.87, 88, 130 However, the exact mechanisms of different 
autophagic phases affecting HBV production remain unclear.  
Endosomal Rab5 and Rab7 have important functions in autophagy regulation. As revealed 
above, Rab5 and Rab7 are related to the formation or the degradation of early autophagic 
bodies and autophagosomes.131, 132 Rab5 has been demonstrated to play an important role in 
autophagosome formation by inhibiting mTOR kinase activity or interacting with Beclin1 and 
Vps34 to form a complex.114, 131 Previous studies have demonstrated that Rab5 is an 
NS4B-interacting protein that is crucial for HCV replication.133  
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However, Rab7 was demonstrated to play a central role in regulating endo-lysosomal 
membrane traffic.110 Rab7 is required for the maturation of late endosomes (LEs)/MVBs as 
well as autophagosomes, directing the trafficking of cargos along microtubules, and 
participating in the fusion step with lysosomes. Moreover, previous reports have 
demonstrated that knockdown of Rab7 led to the blocking of the fusion of autophagosomes 
and lysosomes.121 Thus, we hypothesized that HBV production is modulated either by the 
early autophagic process mediated by Rab5, or the late autophagic process mediated by Rab7. 
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2. Aims of the study 
MiRNAs are highly conserved small noncoding RNAs which are widely expressed in 
multicellular organisms and participate in the regulation of various cellular processes, 
including autophagy and viral replication. Evidently, miRNAs are able to modulate host gene 
expression and thereby inhibit or enhance HBV replication. Our previous work has described 
that miRNAs has complex interconnections with HBV, such as miR-1, miR-125b, and 
miR-449a. We have found that the miR-99 family members are highly expressed in the liver 
tissue. Interestingly, the plasma levels of miR-99 family in the peripheral blood correspond 
with HBV DNA loads. As previous studies identified, the mRNA of IGF-1R, Akt, and mTOR 
as direct targets with binding sites for miR-99 family members. Moreover, it has been 
revealed that HBV replication can be regulated through the PI3K/Akt/mTOR signaling 
pathway, which plays a critical role to induce autophagy. In recent years, it has been found 
that cellular autophagy has a significant impact on HBV replication, as well as viral 
envelopment. This process can be exploited by HBV to facilitate its replication in vitro or in 
vivo. Thus, we addressed whether the miR-99 family regulated HBV replication and analyzed 
the underlying molecular mechanism. Next, we further explored the definite mechanisms of 
different autophagic phases affecting HBV production.  
To elucidate these questions, we have investigated it as the following steps: 
1. Detecting the levels of the miR-99 family expression in primary human hepatocytes and 
different hepatoma cells  
2. Transfecting miR-99 family mimics with or without a HBV genome containing plasmid 
pSM2 into hepatoma cell lines to investigate whether miR-99 family could modulate 
HBV replication in hepatoma cells 
3. Transfecting miR-99 family mimics into hepatoma cell lines to explore the molecular and 
cellular mechanism of miR-99 family modulating HBV replication in hepatoma cells 
4. Treating the hepatoma cell lines and primary human hepatocytes with different 
autophagic inhibitors to investigate the effect on HBV production  
5. Silencing or overexpression of Rab5 and Rab7 to investigate the effect of interfering the 
early or late autophagic phase on HBV production in hepatoma cell lines 
6. Silencing of Rab5 and Rab7 to explore the definite mechanisms of different autophagic 
phases affect HBV production in hepatoma cell lines 
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3. Materials and methods 
3.1 Materials 
3.1.1 Plasmids 
The HBV plasmid pSM2 was kindly provided by Prof. Hans Will as previously reported.134  
Plasmid GFP-LC3 was a gift from Prof. Jiming Zhang, Shanghai, China. Plasmid HBsAg 
expressing mCherry was a gift from Prof. Xinwen Chen, Wuhan, China. Plasmids GFP-Rab7 
WT, GFP-Rab7 DN, GFP-Rab5 CA (Q79L) and GFP-Rab5 DN (Addgene, 35141) were all 
purchased from Addgene (Cambridge, MA, USA).  
pGL3-HBV promoter report plasmids. The luciferase reporter plasmids containing HBV 
promoters were constructed by Dr. Xiaoyong Zhang.23 The regions of HBV core promoter 
(nt1648-1853), HBV X promoter (nt1237-1375), SP1 promoter (nt2224-2784), SP2 promoter 
(nt2814-3123) were amplified from pSM2 plasmid and inserted into pGL3-basic vector 
between Mlu I and Bgl II restriction sites (Promega, Madison, WI) (Figure 3.1, adopted from 
Promega), resulting in the luciferase reporter vectors pSP1, pSP2, pCP and pXP, respectively. 
The Renilla luciferase report plasmid was purchased from Clontech. 
 
Figure 3.1 pGL3-basic vector circle map 
 
pMIR-REPORT system. Full length of HBV genome sequence was generated from pSM2 
plasmid by restriction enzyme SpeI digestion and cloned into the 3' UTR of luciferase gene of 
pMIR-REPORT vector (Invitrogen). Four partial fragments of the HBV sequence (nt2840-837, 
nt837-1840, and nt1830-2849) and HBV RNA 3' UTR sequence (nt1841-1964) were 
amplified from pSM2 plasmid, digested with restriction enzymes MluI and HindIII, and 
cloned into the 3' UTR of luciferase gene by Dr. Xiaoyong Zhang (Figure 3.2).23 
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Figure 3.2 Luciferase reporter plasmids containing HBV fragments 
 
3.1.2 Reagents 
The list of the reagents used in the present study is shown as follows: 
Name Company 
2-propanol Roche 
3-methyladenine (3-MA) Sigma 
4',6-Diamidino-2-phenylindole (DAPI) Sigma 
5× Green GoTaq™ Reaction Buffer  Promega 
10× SDS-PAGE Roche 
10× TBE Buffer Invitrogen 
20× SSC Buffer Invitrogen 
30% Acrylamide Solution BIO-RAD 
Akti-1/2 Merck Millipore 
Alpha-P32 (dCTP) Hartmann Analytic GmbH 
Amersham ECL Western Blotting Reagent GE Healthcare 
AmershamTM Rapid-hyb Buffer GE Healthcare 
Amersham Protran 0.45 NC GE Healthcare 
Chloroform Sigma 
CID1067700 Sigma 
Dimethyl sulfoxide (DMSO) Sigma 
DMEM High Glucose medium PAA Laboratories 
DNAase I Roche 
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D-PBS Invitrogen 
EcoR I and Buffer New England BioLab 
EDTA solution (pH 8.0) AppliChem 
Ethanol AppliChem 
Fetal Calf Serum (FCS) Biochrom 
Hydrochloric Acid Sigma 
HEPES Buffer Solution PAA Laboratories 
IllustraTM MicroSpinTM S-200 HR columns GE Healthcare 
Lipofectamine® 2000 Reagent Invitrogen 
LY294002 Merck Millipore 
Insulin Sigma 
MEM Non Essential Amino Acids PAA Laboratories 
MHY1485 Selleckchem 
NorthernMax®-Gly Sample Loading Dye Thermofisher 
Penicillin/Stretomycin PAA Laboratories 
PeqGOLD Protein-Marker Ⅳ Peqlab 
Positively Chgd. Nylon transfer membrane GE Healthcare 
Proteinase K Qiagen 
QIAprep Spin Miniprep Kit Qiagen 
QIAGEN Plasmid Midi Kit Qiagen 
QIAGEN Plasmid Maxi Kit Qiagen 
Rapamycin Sigma 
Red lysis & Loading Buffer Cell Signaling 
RNase A Qiagen 
Roti-phenol Roche 
RPMI 1640 medium PAA Laboratories 
Salmon Sperm DNA Invitrogen 
SmartLadder Eurogentec 
Sodium Acetate (3M, pH 5.5) Ambion 
Tris buffer (pH7.4 / 8.0 / 8.8) AppliChem 
TRIzol® Reagent Invitrogen 
Trypsin-EDTA PAA Laboratories 
Tween 20 Biochemica 
William’s Medium E Biotech GmbH 
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Yeast RNA Ambion 
 
3.1.3 Buffers 
The list of buffers used in the present study is shown as follows: 
Name Component 
Lysis buffer for HBV EcDNA 
extraction 
50 mM Tris pH 7.4 
1 mM EDTA 
1% Nonidet P-40 
Lysis buffer for HBV core 
particle extraction 
10 mM Tris pH 7.5 
1 mM EDTA  
50 mM NaCl  
8% sucrose 
0.25% Nonidet P-40 
Denaturation buffer 
1.5 M NaCl  
0.5 M NaOH 
Neutralization buffer 
2.0 M NaCl 
1.0 M Tris-base  
2.5% hydrochloric acid 
12 % Separation gel (10 ml) 
3.3 ml ddH2O 
4.0 ml 30% acrylamide  
2.5 ml 1.5M Tris pH 8.8 
100 μl 10% SDS 
100 μl 10% AP 
4 μl TEMED 
5% Concentration gel (5 ml) 
3.15 ml deionized water 
720 μl 30 % acrylamide  
540 μl 1.0 M Tris pH6.8 
45 μl 10 % SDS 
25 μl 10% AP 
5 μl TEMED 
10× Transfer buffer (1 l) 
142.6 g Glycin 
30 g Tris-base 
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3.1.4 Instruments 
The list of all the instruments used in the present study is shown as follows: 
Name Company 
-20 °C Freezer AEG, Germany 
-80 °C Freezer Thermo Forma, Germany 
Amersham HybondTM-N+ GE Healthcare, USA 
BIO WIARD KOJAIR BIO-FLOW Technik, Germany 
Bio Imaging System Syngene, UK 
Bin DER BIOTron Labortechnik GmbH, 
Germany 
CAWOMAT 2000 IR CAWO photochemisches Werk GmbH, 
Germany 
Centrifuge Avanti J-26Xpi Beckman Coulter, Germany 
Centrifuge 5415 R   Eppendorf, Germany 
Centrifuge: Ultracentrifuge Optima L-70K Beckman Coulter, Germany 
CO2 incubator Thermo, Germany 
Cyclone Storage Phosphor Screen Packard, USA 
Hybidization Oven/Sharker Amersham Pharmacia, USA 
Model 785 Vacuum Blotter BIO-RAD, USA 
Mini Protein Tetra Cell BIO-RAD, USA 
Mini Trans-Blot Cell BIO-RAD, USA 
Rotor-Gene Q Qiagen, Germany 
TopCount.NXTTM Packard, UK 
Vacuum Regulator BIO-RAD, USA 
 
3.1.5 miRNAs 
The sequences of all miRNAs and siRNAs used in the present study are shown as follows: 
Name Product Name Company Sequence 5' - 3' 
miR-C miRIDIAN® microRNA 
mimic negative control #1 
GE Healthcare UCACAACCUCCU
AGAAAGAGUAA 
miR-99a-5p Syn-hsa-miR-99a-5p 
miScript miRNA Mimic 
Qiagen AACCCGUAGAUC
CGAUCUUGUG 
miR-99b-5p Syn-hsa-miR-99b-5p 
miScript miRNA Mimic 
Qiagen CACCCGUAGAAC
CGACCUUGCG 
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miR-100-5p Syn-hsa-miR-100-5p 
miScript miRNA Mimic 
Qiagen AACCCGUAGAUC
CGAACUUGUG 
anti-miR-C miScript Inhibitor Negative 
Control 
Qiagen - 
anti-miR-99a-5p Anti-hsa-miR-99a-5p 
miScript miRNA Inhibitor 
Qiagen AACCCGUAGAUC
CGAUCUUGUG 
anti-miR-99b-5p Anti-hsa-miR-99b-5p 
miScript miRNA Inhibitor 
Qiagen CACCCGUAGAAC
CGACCUUGCG 
anti-miR-100-5p Anti-hsa-miR-100-5p 
miScript miRNA Inhibitor 
Qiagen AACCCGUAGAUC
CGAACUUGUG 
 
3.1.6 siRNAs 
The sequences of all siRNAs used in the present study are shown as follows: 
Name Product Name Company Target sequence 
siR-C Allstars Negative Control siRNA Qiagen Proprietary 
siAkt Hs_AKT1_6 FlexiTube siRNA Qiagen AACCAGGACCATGAG
AAGCTT 
simTOR Hs_FRAP1_6 FlexiTube siRNA Qiagen CAGGCCTATGGTCGAG
ATTTA 
siSREBP1 Hs_SREBF1_5 FlexiTube siRNA Qiagen TGCGGAGAAGCTGCC
TATCAA 
siHIF1A Hs_HIF1A_5 FlexiTube siRNA Qiagen AGGAAGAACTATGAA
CATAAA 
siIRF7 Hs_IRF7_1 FlexiTube siRNA Qiagen CCCGAGCTGCACGTTC
CTATA 
sip70S6K Hs_RPS6KB1_5 FlexiTube siRNA Qiagen GGGAGTTGGACCATAT
GAACT 
si4E-BP1 Hs_EIF4EBP1_5 FlexiTube siRNA Qiagen TCGGAACTCACCTGTG
ACCA 
siULK1 Hs_ULK1_6 FlexiTube siRNA Qiagen TGCCCTTTGCGTTATAT
TGTA 
siATG13 Hs_KIAA0652_5 FlexiTube siRNA Qiagen AAGGCGGGAGTGACC
GCTTAA 
siFIP200 Hs_RB1CC1_7 FlexiTube siRNA Qiagen ACGCAAATCAGTTGAT
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GATTA 
siATG5 Hs_APG5L_6 FlexiTube siRNA Qiagen AACCTTTGGCCTAAGA
AGAAA 
siRab5 Hs_RAB5A_5 FlexiTube siRNA Qiagen ATTCATGGAGACATCC
GCTAA 
siRab7 Hs_RAB7_5 FlexiTube siRNA Qiagen CACGTAGGCCTTCAAC
ACAAT 
siSNAP29 Hs_SNAP29_2 FlexiTube siRNA Qiagen CAGAAGATCGACAGC
AACCTA 
siVAMP8 Hs_VAMP8_2 FlexiTube siRNA Qiagen CCGACTAGGCGAATT
CACTTA 
 
3.1.7 Primers  
The sequences of commercial used in the present study are shown as follows: 
Name Product Name Company Cat. No. 
RNU6 Hs_RNU6-2_11 miScript Primer Assay Qiagen MS00033740 
miR-100 Hs_miR-100_2 miScript Primer Assay Qiagen MS00031234 
miR-99a Hs_miR-99a_2 miScript Primer Assay Qiagen MS00032158 
miR-99b Hs_miR-99b_2 miScript Primer Assay Qiagen MS00032165 
β-actin Hs_ACTB_2_SG QuantiTect primer assay Qiagen QT01680476 
ATG13 Hs_ATG13_1_SG QuantiTect Primer Assay Qiagen QT00054194 
FIP200 Hs_RB1CC1_1_SG QuantiTect Primer Assay Qiagen QT00028021 
ATG5 Hs_ATG5_1_SG QuantiTect Primer Assay Qiagen QT00073325 
The synthesized primer pairs were used as follows:  
HBV pgRNA: 5'-TGCCTCATCTGGTTCT-3' (sense) and 5'-CCCCAAWACCCATATA-3' 
(anti-sense); HBx: 5'-CCGTCTGTGCTCATCT-3' (sense) and 5'-TAATCTCCTCAACTCC 
-3' (anti-sense).  
 
3.1.8 Antibodies  
Antibodies against the following proteins were used: 
Name Source Company 
anti-HBcAg  Rabbit pAb Abcam 
Akt Rabbit pAb Cell Signaling 
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mTOR Rabbit pAb Cell Signaling 
ULK1 Rabbit pAb Abcam 
p70S6 K Rabbit pAb Cell Signaling 
anti-Rab5 Rabbit pAb Cell Signaling 
anti-Rab7 Rabbit pAb Cell Signaling 
anti-SNAP29 Rabbit pAb Sigma 
anti-VAMP8 Rabbit pAb Sigma 
anti-LAMP1 Rabbit pAb Sigma 
anti-p62 Rabbit pAb Abcam 
anti-LC3 Rabbit pAb MBL International 
anti-β-actin Mouse mAb Sigma 
phospho-Rb Rabbit pAb Cell Signaling 
phospho-Akt Rabbit pAb Cell Signaling 
phospho-mTOR Rabbit mAb Cell Signaling 
phospho-p70S6 K Rabbit mAb Cell Signaling 
phospho-ULK1 Rabbit mAb Cell Signaling 
 
3.2 Methods 
3.2.1 Cell culture and transfection 
All cell cultures were maintained at 37 ºC in a humidified atmosphere containing 5% CO2. 
The human hepatoma cell line HepG2.2.15, which harbors integrated dimers of the HBV 
genome (GenBank Accession Number: U95551) and shows a constantly detectable level of 
HBV replication, was cultured in RPMI-1640 medium (Gibco) with 10% fetal bovine serum 
(FBS), 100 U/ml penicillin, 100 µg/ml streptomycin (Gibco), and 500 µg/ml G418 (Merck 
Millipore). Another human hepatoma cell line Huh7 was grown in Dulbecco’s Modified 
Eagle’s Medium (Gibco) supplemented with 10% FBS. Primary hepatocytes were kindly 
provided by Dr. Ruth Broering, University Hospital Essen.  
The cultivation and viral infection of PHHs are shown as follows: 
(1) 2 day before HBV infection, separate the PHHs from patient and seed them into 12-well 
plate. 
(2) 1 day before HBV infection, Wash the cells with PBS one time. PHHs were incubated 
with 20 μl HBV viron (2×1010 copies/ml, 1:50) and 1 ml WM1 medium (WM2 medium + 
PEG 8000) at 37 °C for 24 h. 
(3) At the end of incubation (0 day post HBV infection), wash the cells with PBS 3 times. 
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Then PHHs were incubated with 1 ml WM2 medium. 
(4) At 2, 4, 6, day post HBV infection, harvest the supernant, wash the cells with PBS 1 time, 
and change new medium with 1 ml WM2 medium. 
(5) At 10 day post HBV infection, harvest the supernant to detect HBsAg and HBeAg, wash 
the cells with PBS 1 time, and change with 1 ml WM2 medium including autophagy 
inhibitors (including Rapamycin, CID, and CQ) for 48 h or for 72 h. 
(6) At 13 day (72 h post treatment), collect the supernatant and cells for further detection. 
 
Plasmids, miRNAs, or siRNAs were transfected into cells at indicated concentrations using 
the Lipofectamine 2000 transfection reagent (Invitrogen) according to the manufacturer’s 
instructions. The protocol of transfection used in this study is as follows: 
(1) 1 day before transfection, seed HepG2.2.15 cells into 6-well plate. 
(2) Wash the cells with PBS once.  
(3) Dilute 1.5 μl of 20 μM miR-100 mimics into 250 μl Opti-MEM. 
(4) Dilute 4 μl Lipo2000 into 250 μl Opti-MEM, incubate them at RT for 5 min. 
(5) Add 250 μl Opti-MEM (diluted with Lipo2000) into 250 μl Opti-MEM (diluted with 
miR-100), incubate at RT for 20 min. 
(6) Discard the old medium from 6-well plate, and wash with PBS once.  
(7) Add 1 ml Opti-MEM into each well, and then add 500 μl Lipo2000-miRNA complex 
(from step 5) drop by drop. 
(8) 4-6 hours later, change new medium with 2 ml complete 1640 medium, then put the cells 
at 37 ºC in a humidified atmosphere. 
 
3.2.2 Plasmid extraction 
The transformation of plasmid into E.coli strains (DH5α, Invitrogen) was performed 
according to manufacturer’s instructions.  
(1) Thawed 50 μl aliquots of bacteria on ice, mixed gently with 2-3 μl of ligation mixture, 
and incubated on ice for 30 min.  
(2) Heat shock at 42 °C for 30 s, followed by a subsequent incubation on ice for 2 min.  
(3) Added 200 μl of SOC medium (Invitrogen, Switzerland) into the cells, and then shake at 
37 °C for 2 h. Using a sterile spatula, the complete mixture was spread over an LB-agar 
plate containing a selective antibiotic (100 μg/ml of ampicillin or 50 μg/ml kanamycin).  
(4) The plates were incubated at 37 °C overnight.  
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(5) One bacterial colony was picked up from the LB agar plate using a sterile pipette tip and 
transferred into the flask with LB-medium containing selective antibiotic.  
(6) Prepare 2 ml culture LB medium for mini extraction of plasmid, 50 ml for midi extraction, 
and 250 ml for maxi extraction, respectively.  
(7) Put the LB medium into the shaker, and incubate at 37 °C overnight.  
(8) The plasmid DNA was extracted using Qiagen plasmids kits according to the 
manufacturer protocol. DNA concentration was quantified by spectrophotometric OD 
260 nm measurement as follows: 
Concentration [μg/μl] = OD 260 nm × dilution factor × 50  
(9) Finally, purified plasmid DNA was confirmed by restriction enzyme digestion. 
 
3.2.3 RNA extraction 
Total cellular RNA was extracted by using Trizol reagent (Invitrogen, Switzerland), followed 
by digestion with the DNase Set (Roche, Switzerland). The protocol of RNA extraction in 
detail is as follows: 
(1) Collect the cells in 12-well plate with 500 µl Trizol reagent by pipetting the cells up and 
down several times. 
(2) Incubate the homogenized sample for 5 min at RT to permit complete dissociation of the 
nucleoprotein complex. 
(3) Add 100 µl chloroform, and shake tubes vigorously by hand for 15 s.  
(4) Incubate at RT for 2-3 min. Centrifuge at 12,000 g at 4 °C for 15 min. 
(5) Transfer the aqueous phase to a new 1.5 ml EP tube, and add 250 µl isopropanol.  
(6) Incubate at RT for 10 min. Centrifuge at 12,000 g at 4 °C for 10 min. 
(7) Remove the supernatant from the tubes, and wash the RNA pellet with 100 µl 75% 
ethanol. 
(8) Vortex the samples briefly, and centrifuge at 12,000 g at 4 °C for 5 min. 
(9) Discard the supernatant, and air dry the RNA pellet for 5-10 min. 
(10) Finally, elute the RNA into 50 µl RNase free water. Measure the concentration of RNA 
(1:50 dilution). 
(11) The concentration of all samples is then diluted into 100 ng/µl by adding RNase free 
water, and then store in -80 °C or for real-time RT-PCR. 
 
3.2.4 Real-time RT-PCR 
Quantitative real-time RT-PCR 
31 
 
The levels of relative mRNA expression in cells were determined by quantitative real-time 
PCR analysis using commercial QuantiTect Primer Assays (Qiagen, Germany). Finally, the 
ratio of mRNA levels was normalized to internal control beta-actin.  
The protocol of real-time RT-PCR for RNA is as follows: 
Quantification of the mature miRNAs was performed by using QuantiFast SYBR Green 
RT-PCR kit (Qiagen). Reaction mixture as follows: 
Component  Volume (20 μl)  
2× SYBR Green RT-PCR Master Mix  10 μl 
10× primers  2 μl 
QuantiFast RT mix  0.2 μl 
Template RNA  1 μl 
RNase-free water  6.8 μl 
cycler conditions: 
1) 50 °C, 10 min for reverse transcription 
2) 95 °C, 5 min for initial activation of hotstar Taq DNA polymerase 
3) 95 °C, 10 s  for denaturation 
4) 60 °C, 30 s  for annealing and extension step 
40 cycles for DNA (step 3 to 4) 
 
Quantitative miScript real-time RT-PCR 
The levels of relative mature miRNA expression were determined by quantitative miScript 
real-time PCR analysis using commercial miScript Primer Assay (Qiagen, Germany). Finally, 
the ratio of miRNA levels was normalized to internal control RNU6 expression. The protocol 
of miScript real-time RT-PCR is as follows: 
Total RNA is extracted from cells by Trizol reagent as mentioned above.  
1 μg total RNA is reverse-transcribed into cDNA according to miScript II RT Kit (Qiagen). 
The reverse-transcription master mixes on ice as follows: 
Component Volume (20 μl) 
5× miScript HiSpec Buffer 4 μl 
miScript Reverse Transcriptase Mix 1 μl 
Template RNA 1 μl 
RNase-free water 14 μl 
cycler conditions: 
37 °C for 60 min  
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95°C for 5 min  
Quantification of the mature miRNAs was performed by miScript SYBR Green PCR kit 
(Qiagen). Reaction mixture as follows: 
Component Volume (20 μl) 
2× SYBR Green RT-PCR Master Mix 10 μl 
10× miScript Universal Primer 2 μl 
10× miScript Primer Assay 2 μl 
Template RNA 2 μl 
RNase-free water 4 μl 
Cycle parameter:  
1) 95 °C for 15 min  
2) 94 °C for 15 s  for denaturation 
3) 55 °C for 30 s  for annealing 
4) 70 °C for 30 s  for extension 
40 cycles (step 2 to 3) 
For standard curve:  
1) Dilute the synthetic miRNA mimics into 1010 copies/μl.  
2) Prepare 20 μl reverse-transcription reaction as mentioned above, using 5 μl synthetic 
miRNA (1010 copies/μl) and 50 ng carrier bacterial RNA (yeast mRNA, 10 μg/μl).  
3) Incubate at 37 °C for 60 min. Incubate at 95°C for 5 min to inactivate and place on ice.  
4) Add 480 μl of 1 ng/μl bacterial carrier RNA to the 20 μl reaction. Mix gently by pipetting 
up and down and centrifuge briefly to yields the cDNA (108 copies/μl). 
5) Using the diluted cDNA mix (108 copies/μl) and carrier RNA (1 ng/μl), prepare a series of 
standard curve (108, 107, 106, 105, 104, 103 copies/μl) to run real-time miScript RT-PCR by 
miScript SYBR Green PCR kit (Qiagen). 
 
3.2.5 Analysis of HBV gene expression 
Quantification of HBsAg and HBeAg 
The levels of HBsAg and HBeAg in the culture medium were determined using the Architect 
System and the HBsAg and HBeAg CMIA kits (Abbott Laboratories, Germany) according to 
the manufacturer’s instructions.  
 
Quantification of HBV DNA 
HBV progeny DNA was extracted from culture medium using the DNA Blood Mini Kit 
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(Qiagen) and quantified by quantitative real-time polymerase chain reaction (Invitrogen). 
HBV DNA was extracted from intracellular core particles in hepatoma cell lines and detected 
by quantitative real-time PCR or Southern blotting analysis (mention below). 
The protocol of quantitative real-time PCR for quantification of total HBV DNA levels is 
as follows: 
Purification of HBV DNA from culture medium: 
(1) Pipette 20 μl QIAGEN Protease into the bottom of a 1.5 ml EP tube. 
(2) Add 200 μl culture medium to the EP tube. 
(3) Add 200 μl Buffer AL to the sample. Mix by pulse-vortexing for 15 s. 
(4) Incubate at 56 °C for 10 min. 
(5) Add 200 μl ethanol (96–100%) to the sample, and mix again by pulse-vortexing for 15 s.  
(6) Carefully apply the mixture from step 5 to the QIAamp spin column without wetting the 
rim, close the cap, and centrifuge at 6,000 g for 1 min. Place the QIAamp spin column in a 
clean 2 ml collection tube, and discard the tube containing the filtrate. 
(7) Carefully open the QIAamp spin column and add 500 μl Buffer AW1 without wetting the 
rim. Close the cap and centrifuge at 6,000 g for 1 min. Place the QIAamp spin column in a 
clean 2 ml collection tube, and discard the collection tube containing the filtrate. 
(8) Carefully open the QIAamp spin column and add 500 μl Buffer AW2 without wetting the 
rim. Close the cap and centrifuge at full speed for 3 min.  
(9) Place the QIAamp spin column in a new 2 ml collection tube and discard the collection 
tube with the filtrate. Centrifuge at full speed for 1 min. 
(10) Place the QIAamp spin column in a clean 1.5 ml EP tube, and discard the collection tube 
containing the filtrate. Carefully open the QIAamp spin column and add 50 μl ddH2O. 
Incubate at RT for 1 min, and then centrifuge at 6,000 g for 1 min. 
(11) Store the samples at -20 °C or using as template for real-time PCR for detecting HBV 
progeny DNA directly. 
Reaction mixture for real-time PCR: 
Component Volume (20 μl) 
2× UDG mix 10 μl 
Hope-forward prime 0.4 μl 
Hope-reverse prime 0.4 μl 
MgCl2 0.8 μl 
BSA 1 μl 
Template 2 μl 
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Aqua 5.4 μl 
cycler conditions: 
(1) 95 °C, 15 s for denaturation 
(2) 60 °C, 15 s for annealing  
(3) 72 °C, 10 s for extension step 
45 cycles (step 1 to 3) 
 
3.2.6 Southern blotting analysis 
HBV replicative intermediates from intracellular core particles were extracted from hepatoma 
cell lines and detected by Southern blotting, respectively. The encapsided HBV DNA in 
nucleocapsids was also detected by Southern blotting. However, HBV nucleocapsid in cell 
lysates was analyzed in a native agarose gel and then detected by western blotting analysis. 
The protocol of Southern blotting for detecting HBV replication is as follows: 
EcDNA extraction: 
(1) 3 or 4 days post-transfection, wash the cells in 6-well plate with PBS 1 time. 
(2) Add 800 µl iced lysis buffer and incubate on ice for 10 min. 
(3) Collect the cell lysates into 2 ml EP tube, vortex vigorously for 15 s, and then incubate on 
ice for 10 min. 
(4) Centrifuge at 13,200 rpm for 2 min. 
(5) Transfer the supernatant to a new 2 ml EP tube, then add 8 µl of 1 M MgCl2 and 8 µl of 
10 mg/ml DNase I, mix gently, and incubate for 30 min at 37 °C. 
(6) Shortly centrifuge, and add 40 µl of 0.5 M EDTA (pH 8.0) to a final concentration of 25 
mM, mix by vortex. 
(7) Shortly centrifuge, and add 80 µl 10% SDS, mix by vortex. 
(8) Shortly centrifuge, and add 20 µl 20 mg/ml proteinase K. 
(9) Incubate at 55 °C for 2 h. 
(10) Phenol/chloroform extraction, vortex and static for 2 min, then centrifuge at 13,000 rpm 
at RT for 8 min.  
(11) Suck up the first layer liquid and add 0.7 V of isopropanol, 0.1 V of 3 M NaAc (pH5.2) 
and 2 µl of 10 mg/ml yeast RNA, incubate over night at -20 °C.  
(12) 13,200 rpm at 4 °C for 15 min, discard the supernatant carefully. 
(13) Wash the pellet with 1 ml 75% ethanol, up and down 2 times gently without disrupt the 
whole pellet, centrifuge at 8,000 rpm at RT for 5 min. Discard the supernatant carefully, 
then air dry for 5-10 min.  
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(14) Dissolve the pellet in 15 µl TE buffer. 
(15) Add 5 µl 5× green loading buffer, scrape on tube shelf and short centrifugate.  
 
Run agarose gel: 
(1) Prepare 1% agarose gel. 
(2) Electrophoresis for 1.5-2 h at 50 V. 
(3) Wash with ddH2O one time, then denaturation for 30 min at RT with gentle agitation. 
(4) Wash with ddH2O one time, then neutralization for 30 min at RT with gentle agitation. 
(5) Wash the agarose gels with ddH2O one time, and then soak in 20× SSC.  
(6) Transfer the membranes (from down to up including: white fiberboard, filter paper, 
Nylon membrane, green plastic membrane and the agarose gels), cover the cover. 13Hg 
for 2 h. 
(7) Fix DNA on the membranes at 150 J/cm2 2 times. 
 
Hybridization probe preparation: 
(1) Digest plasmid pSM2 (1 μg/μl) which contain HBV dimer by restriction enzyme EcoR I. 
Component Volume (100 μl) 
EcoR I 1 μl 
10× NEB 2 10 μl 
pSM2 10 μl 
Aqua 79 μl 
(2) After digestion at 37 °C for 2 h, 25 μl 5× green loading buffer was added. Run 0.8% 
agarose gel at 130 V for 2 h to separate two bands (3.2 kb for HBV fragment and 2.7 kb 
for vector), and cut 3.2 kb band for agarose gel extraction.  
(3) Agarose gel extraction to quantify the HBV fragment concentration and dilute into 25 
ng/μl. The HBV fragments were put in -80 °C for long-term storage or used directly for 
Southern blotting hybridization. 
 
Hybridization: 
(1) Dilute 5 µl HBV DNA probe (5 ng/µl) into 41 µl TE in 1.5 ml tube. 
(2) Mix and then denature at 95 °C for 5 min. 
(3) Then snap cool the DNA by placing on ice for 5 min after denaturation.  
(4) Prehybridize the membranes in 10 ml Rapid-Hyb buffer (Amersham) at 65 °C for 10-20 
min. 
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(5) Centrifuge briefly the denatured DNA, and add into the reaction tube (GE Healthcare) 
which contains polymerase. 
(6) Add 2 µl/reaction α-32P dCTP into the reaction tube. 
(7) Incubate at 37 °C for 10 min. 
(8) Stop the reaction by adding 5 µl of 0.2 M EDTA. 
(9) Loosen the cap of column 1/4 turn, snap off the bottom closure of the microspin columns, 
and centrifuge for 1 min at 3,000 rpm. 
(10) Place the column in 1.5 ml tube with 100 µl of 10 mg/mL salmon sperm, and slowly 
apply the reaction sample to the resin.  
(11) 3,000 rpm for 2 min. 
(12) For use in hybridization, denature the labeled DNA by heating to 95 °C for 5 min, then 
snap cool on ice for 5 min.  
(13) Add purified labeled DNA to the pre-hybridization solution by directly dropping into 
hybridization tube. 
(14) Hybridize at 65 °C overnight.  
(15) Wash the membranes with 50 ml wash buffer I (2× SSC + 0.1% SDS) at RT for 30 min 2 
times. 
(16) Wash the membranes with 50 ml wash buffer II (0.2× SSC + 0.1% SDS) at 65 °C for 30 
min 2 times. 
 
3.2.7 Northern blotting analysis 
HBV transcripts were extracted from hepatoma cell lines and detected by northern blotting.  
1. The protocol of northern blotting (Glyoxal method) for HBV transcription is as follows: 
(1) Wash gel electrophoresis chamber, tray and combs with ddH2O 3 times, with 
DEPC-water for 2 times. Then dry them in ventilate hood. 
(2) Prepare 1.2% agarose gel. 
(3) Weight 1.2 g agarose, and add 100 ml 1× Gly prep/Running Buffer. 
(4) Boil them in microwave oven, cool to 50~60 °C, and then pour into chamber.  
(5) Prepare RNA samples: 10 µl RNA (1 µg/µl) + 10 µl Glyoxal load Dye + 1 µl EB.  
(6) Incubate at 50 °C for 30 min, and then put into ice for 10 min.  
(7) Electrophoresis: Add 1× Gly prep/Running Buffer, 60 V at 4 °C for 4 h. 
(8) Detect 18 s and 28 s quickly by Gel Imager. 
(9) Transfer.  
(10) Wash gel with DEPC water. 
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(11) Shake gently in 20× SSC (diluted by DEPC water) for 1 h.  
(12) Prepare to put the positive-charged NC membrane into 20× SSC, and then do membrane 
transferring just like Southern blotting. 
(13) Ultraviolet crosslinking like Southern blotting. 
(14) Hybridization processes are just like Southern blotting. 
 
3.2.8 Western blotting analysis 
Western blotting analysis was performed to detect the relative protein expression. Briefly, 
after transfection or treatment, cells were washed with phosphate-buffered saline and lysised 
with 1× lysis buffer (Cell Signaling Technology, USA). Protein samples were resolved by 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis and then electrotransferred to 
nitrocellulose membranes. The membranes were incubated with the indicated primary 
antibodies overnight at 4 °C after being blocked with 5% milk in 1× TBST. The membranes 
were washed with 1× TBST and incubated (as appropriate) with a secondary 
peroxidase-affiniPure Rabbit anti-mouse IgG antibody (Jackson ImmunoResearch West 
Grove, USA) or a peroxidase-affiniPure goat anti-rabbit IgG antibody (Jackson 
ImmunoResearch). Immunoreactive bands were visualized using an enhanced 
chemiluminescence system (GE Healthcare, UK). 
The protocol of western blotting in detail is as follows: 
(1) Aspirate culture media from 12-well plate, wash the cells with PBS, and aspirate it. 
(2) Lyses the cells by adding 100 µl of 1× red lysis buffer (Cell Signaling). Scrape off the 
cells from the plate immediately, and transfer them to a new 1.5 ml centrifuge tube on 
ice. 
(3) Heat the samples at 95 ºC for 10 min; then cool on ice. 
(4) Prepare four 12%-15% separate gel.  
(5) Load protein samples into SDS-PAGE gel: 3 µl protein marker/well, 10 µl sample/well 
for purpose band, and 3 µl sample/well for beta-actin detection.  
(6) Run at 100 V for 30 min firstly, and then change to 130 V for 1.5 h.   
(7) Transfer to NC membrane, 250 mA for 1 h.            
(8) Incubate the membranes in 5% milk at RT for 1 h.  
(9) Wash the membranes with 1× TBST. 
(10) Incubate the membranes in primary antibody (1:1000, by 0.25% milk in 1×TBST) at 4 ºC 
overnight with gentle agitation. 
(11) Wash the membranes with 1× TBST for 10 min 3 times. 
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(12) Incubate the membranes in 5 ml HRP-conjugated secondary antibody (1:15000, by 0.25% 
milk in 1× TBST) at RT with gentle agitation for 1 h.  
(13) Wash the membranes with 1× TBST for 10 min 3 times. 
(14) Put the membrane in plastic wrap and add 600 µl ECL buffer/membrane, then put into 
black-box for exposure. 
 
3.2.9 Luciferase reporter gene assay 
The Dual-Glo luciferase reporter assay (Promega) was used to detect the firefly luciferase 
activity and the internal control Renilla luciferase activity. The firefly luciferase reporter 
plasmids pSP1, pSP2, pCP, pXP (containing HBV promoters), and pmiR-HBV FL, 
pmiR-HBV1, pmiR-HBV2, pmiR-HBV3, and pmiR-HBV3'UTR (containing full length 
genome, and partial genome fragments) were generated previously as described 23. 
The protocol of Dual-Glo luciferase reporter assay is as follows: 
(1) 48 h post transfection, discard the culture medium, wash the cells with PBS once, and 
remove it. 
(2) Add 75 µl PBS for each well.  
(3) Add 75 µl Dual-Glo luciferase Reagent to each well.  
(4) Punch the cells with tip into 96-well black plate from 24-well plate. 
(5) Cap the plate and measure the firefly luminescence.  
(6) Add 75 µl Dual-Glo stop reagent to each well and wait for at least 10 min then measure 
Renilla luminescence.  
(7) Calculate the ratio of firefly to Renilla. 
 
3.2.10 Microscopy image acquisition and quantification 
For fluorescence staining, Huh7 cells were grown on cover slips and cotransfected with the 
plasmid GFP-LC3 and miRNAs or siRNAs. After transfection for 48 h, cells were fixed in 
4% paraformaldehyde for 10 min, and permeabilized with 0.1% Triton X-100 for 10 min. The 
nuclei were stained with 4', 6-Diamidino-2-phenylindole (DAPI), and the distribution of the 
GFP-tagged LC3 protein was visualized with confocal microscope (LSM 710; Carl Zeiss) 
with objectives Plan-Apochromat 63×/1.40 oil Iris M27. Images were acquired by ZEN 
acquisition software (2012; Carl Zeiss) and analyzed by ImageJ software. The images were 
not manipulated other than contrast and brightness adjustments. For quantification of the 
number of the GFP-LC3 puncta, approximately 50 cells were recorded and analyzed by 
ImageJ software.109 
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The protocol of immunofluorescence staining in detail is as follows: 
(1) Fix the cells with 200 µl 4% formaldehyde, incubate at RT for 10 min. 
(2) Wash the cells with 200 µl PBS for 5 min 3 times. 
(3) Incubate with 200 µl 0.1% Triton X-100 at RT for 10 min.  
(4) Wash the cells with 200 µl PBS for 5 min 3 times. 
(5) Block with 150 µl 5% FBS in PBS, at RT for 30 min. 
(6) Wash the cells with 200 µl PBS for 5 min 3 times. 
(7) Incubate with 150 µl first-antibody (1:200) at RT for 1 h.  
(8) Wash the cells with 200 µl PBS for 5 min 3 times. 
(9) Incubate with 150 µl second-antibody (1:200) with FITC-labeled at RT for 1 h. 
(10) Incubate with 150 µl DAPI (1:1000) at RT for 10-15 min. 
(11) Wash the cells with 200 µl PBS for 5 min 3 times. 
(12) Add 1 drop fluorescent mounting medium (Dako) onto the slide. Cover with glass lip and 
seal with nail polish. 
 
3.2.11 Statistical analysis 
Statistical analyses were performed using Graph Pad Prism software version 6 (La Jolla, CA, 
USA). Analysis of variance with two-tailed Student’s t test or by one- or two-factor ANOVA 
analysis was used to determine significant differences. Differences were considered as 
statistically significant when P < 0.05. All experiments were repeated independently at least 3 
times. 
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4. Results 
4.1 Low expression of mature miR-100 and miR-99a in hepatoma cells 
Previous data have identified members of the miR-99 family, including miR-100, miR-99a, 
and miR-99b, as tumor suppressors.135-138 Their expression levels in HCC tissue were lower 
than that observed in normal liver tissue.137, 138 
To compare expression levels of miR-99 family members in normal human hepatocytes 
and hepatoma cells, we determined their expression levels in primary hepatocytes (PHHs) and 
3 different hepatoma cell lines Huh7, HepG2, and HepG2.215 cells by quantitative miScript 
real-time reverse transcriptase polymerase chain reactions (RT-PCR). Mature miR-100 and 
miR-99a were expressed at approximately 20- and 50-fold higher levels in PHHs than in 
hepatoma cells, respectively (Figure 4.1, A and B). However, miR-99b expression was not 
decreased in hepatoma cells; indeed, it was significantly higher in HepG2.2.15 cells than in 
primary human hepatocytes. Collectively, these data suggest that the expression of the miR-99 
family is strongly dysregulated in hepatoma cells, compared to that in PHHs. 
 
Figure 4.1 Low expression of mature miR-100 and miR-99a in hepatoma cells 
The expression levels of miR-99 family members miR-100, -99a, and -99b in PHHs and hepatoma cell lines 
Huh7, HepG2, and HepG2.2.15 were determined by miScript real-time polymerase chain reaction. (A) The 
measured copy numbers of miR-100, -99a, and -99b were normalized to those of U6 snRNA (RNU6). RNU6 
was used as an endogenous control. (B) The relative expression levels of miR-100, -99a, and -99b in cells 
compared to that of HepG2.2.15 (set as 1). The analyses were performed in triplicate. * P < 0.05, ** P < 0.01, 
*** P < 0.001. 
 
4.2 The miR-99 family promotes HBV replication 
4.2.1 The miR-99 family promotes HBV protein production, DNA replication and 
progeny secretion 
Next, we investigated whether miR-99 family members regulated HBV replication in 
different hepatoma cells. Synthetic mimics of miR-100, miR-99a, and miR-99b were 
transfected into HepG2.2.15 cells at a final culture supernatant concentration of 40 nM. HBV 
replicative intermediates (HBV RIs) were isolated at day 4 post-transfection and analyzed by 
Southern blotting. As compared to transfection with a miRNA control (miR-C), the mount of 
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HBV RIs, HBV DNA in the supernatant, and HBsAg/HBeAg secretion significantly 
increased following ectopic expression of miR-99 family members (Figure 4.2, A). In Huh7 
hepatoma cells, miR-99 family mimics could also promote HBV replication and gene 
expression if co-transfected with a replication competent clone of HBV plasmid pSM2 
(Figure 4.2, B). Western blotting analysis of cell lysates indicated the hepatitis B core antigen 
(HBcAg) expression in HepG2.2.15 cells obviously increased after transfection with miR-99 
family members (Figure 4.3).  
 
Figure 4.2 The miR-99 family promotes HBV DNA replication and gene expression 
(A) HepG2.2.15 cells were transfected with miR-99 family mimics or a nonspecific miRNA control (miR-C) at a 
final concentration of 40 nM and harvested 96 h later. (B) Huh7 cells were co-transfected with 1.5 µg of pSM2 
plasmid and miRNA mimics at a final concentration of 40 nM, and harvested after 72 h. HBV replicative 
intermediates inside the cells were isolated and detected by Southern blotting. HBV DNA levels in the 
supernatant were determined by quantitative real-time polymerase chain reaction. The levels of HBsAg and 
HBeAg in culture supernatant were determined by chemiluminescence immunoassay. S/CO = signal to cutoff 
ratio; RC, relaxed circular DNA; SS = single-stranded DNA. *, # P < 0.05; **, ## P < 0.01; ***, ### P < 0.001. 
 
 
Figure 4.3 The miR-99 family promotes HBcAg expression 
HepG2.2.15 cells were transfected with miR-99 family mimics or a nonspecific miRNA control (miR-C) at a 
final concentration of 40 nM, and cell lysates were harvested at 72 h post-transfection. The analysis of HBcAg 
expression was performed by western blotting. Beta-actin was used as the loading control.  
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4.2.2 The miR-99 family promotes HBV replication in dose dependence 
Furthermore, HepG2.2.15 cells were transfected with different doses of miR-99 family 
mimics (at 10, or 40 nM) or miRNA control miR-C, and harvested after 96 h. The results 
revealed the miR-99 family members enhanced HBV replication and secreted HBsAg and 
HBeAg in a dose-dependent manner in HepG2.2.15 cells (Figure 4.4). Based on these results, 
subsequent experiments were performed mainly with HepG2.2.15 cells.  
 
Figure 4.4 The miR-99 family promotes HBV DNA replication in dose dependence 
HepG2.2.15 cells were transfected with different doses of miR-99 family mimics (at 10, or 40 nM) or miRNA 
control miR-C, and harvested after 96 h. HBV replicative intermediates inside the cells were isolated and 
detected by Southern blotting. The levels of HBsAg and HBeAg in the supernatant were determined by 
chemiluminescence immunoassay. S/CO = signal to cutoff ratio; RC, relaxed circular DNA; SS = single-stranded 
DNA. *, # P < 0.05; **, ## P < 0.01; ***, ### P < 0.001. 
 
4.2.3 The miR-99 family inhibitors decrease HBV DNA replication and gene 
expression 
Finally, the inhibitors of miR-100, miR-99a, and miR-99b could obviously inhibit the 
secretion of HBsAg and HBeAg and HBV replication in HepG2.2.15 cells (Figure 4.5), as 
they decreased the levels of miR-99 family expression (Figure 4.6). Together, these results 
support that the miR-99 family effectively promotes HBV replication, gene expression and 
progeny secretion. 
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Figure 4.5 The miR-99 family inhibitors decrease HBV DNA replication and gene expression 
HepG2.2.15 cells were transfected with miR-99 family inhibitors or a miRNA inhibitor control anti-miR-C at 40 
nM, and harvested after 96 h. HBV replicative intermediates inside the cells were isolated and detected by 
Southern blotting. The levels of HBsAg and HBeAg in the supernatant were determined by chemiluminescence 
immunoassay. S/CO = signal to cutoff ratio; RC, relaxed circular DNA; SS = single-stranded DNA. * P < 0.05, 
** P < 0.01, *** P < 0.001. 
 
 
Figure 4.6 MiR-99 family inhibitors affect the expression of miR-99 family members 
HepG2.2.15 cells were transfected with inhibitors of miR-100, -99a, -99b or control anti-miR-C at 40 nM, and 
harvested at 72 h. The levels of miR-99 family expression were determined by miScript real-time polymerase 
chain reaction with RNU6 as the normalization control. The relative expression levels of miR-100, -99a, and 
-99b were compared to that of anti-miR-C transfection (set as 1). 
 
4.3 The miR-99 family enhances HBV replication through directly inhibiting the 
IGF-1R/PI3K/Akt/mTOR signaling pathway 
4.3.1 The miR-99 family does not promote HBV transcription and promoter activity 
Several cellular miRNAs have been shown to inhibit or enhance viral replication by directly 
targeting viral RNAs.26, 139 Although HBV is a DNA virus, its transcripts might be targeted 
and modulated by cellular miRNAs.25, 26 However, no potential binding site (UACGGGU) of 
the seed sequence of the miR-99 family members was found in the HBV genomic sequencing 
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the available prediction software packages (MiRanda, TargetScan, and Pictar) for studying 
miRNA-mRNA interactions.8 In agreement, co-transfection of pMIR-REPORT plasmids 
harboring the full-length HBV genome or HBV genome fragments with miR-99 family 
mimics into HepG2.215 cells did not decrease the luciferase activities of different HBV 
fragments (Figure 4.7, A). Thus, we found no evidence for a direct interaction between HBV 
transcripts or the HBV genome with miR-99 family members, which may lead to regulation 
of HBV gene expression or replication. 
Next, the effect of the miR-99 family members on the activities of HBV promoters was 
measured in Dual-Glo luciferase report assays. Consistently, we found that the luciferase 
activities of the HBV SP1, SP2, Core, and X promoters also were not significantly changed 
by ectopic expression of miR-99 family members (Figure 4.7, B). 
 
Figure 4.7 The miR-99 family does not promote HBV promoter activity 
(A) HepG2.2.15 cells were co-transfected with miR-99 family mimics or control miR-C at 40 nM, 
pMIR-REPORT plasmids including pMIR-Luc, -HBV FL, -HBV1, -HBV2, -HBV3, or -HBV 3' UTR, and 
Renilla as an internal control for 48 h. Dual-Glo luciferase report assay was performed to measure the firefly and 
Renilla luciferase activities. The results were calculated by fold change, and normalized to the miRNA control 
samples. (B) HepG2.2.15 cells were co-transfected with miR-99 family mimics or control miR-C at 40 nM, HBV 
promoter luciferase reporters containing the regions of pSP1, pSP2, pCP, and pXP, and Renilla as an internal 
control. The determination of luciferase activities was described above. * P < 0.05, ** P < 0.01, *** P < 0.001. 
The effect of miR-99 family members on the different steps of HBV life cycle was further 
examined. The levels of HBV RNA were separately determined by northern blotting (Figure 
4.8, A) and real-time RT-PCR (Figure 4.8, B) in HepG2.2.15 cells. We observed that the 
levels of HBV RNA remained unchanged after transfection of miR-99 family members, 
indicating that these miRNAs did not promote HBV transcription, further implying that the 
miR-99 family enhanced HBV replication through some other mechanism(s). 
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Figure 4.8 The miR-99 family does not promote HBV transcription 
HepG2.2.15 cells were transfected with miR-99 family mimics or the miR-C control at 40 nM and harvested 
after 72 h. (A) HBV RNAs were detected by northern blotting analysis, using 28S and 18S RNAs as loading 
controls. (B) HBV pregenomic RNA (pgRNA) and HBx RNA levels were analyzed by real-time reverse 
transcriptase polymerase chain reaction, using primers matching to the pgRNA-specific region and HBx region 
(covering all transcripts), respectively. * P < 0.05, ** P < 0.01, *** P < 0.001. 
 
 
Figure 4.9 The miR-99 family promotes HBV capsid formation 
HepG2.2.15 cells were transfected with miR-99 family mimics or the miR-C control at 40 nM and harvested 
after 72 h. Cell lysates from HepG2.2.15 cells were harvested at 72 h post transfection. Analysis of HBV 
nucleocapsid and the encapsidated HBV DNA was detected by western and Southern blotting, respectively. 
Beta-actin was used as the loading control.  
Strikingly, ectopic expression of miR-99 family members strongly increased the amount of 
HBV capsid and capsid-associated HBV DNA detected by western and Southern blotting 
analysis, respectively (Figure 4.9). Taken together, these results suggest that the miR-99 
family members promote HBV replication at post-transcriptional steps, such as capsid 
formation. 
 
4.3.2 HBV replication is enhanced by inhibiting PI3K/Akt/mTOR signaling pathway 
Previous studies have demonstrated that HBV replication and HBsAg production could be 
regulated through the PI3K/Akt/mTOR signaling pathway.80, 140 Clearly, treatment of 
HepG2.215 cells for 48 h by using PI3K, Akt, and mTOR chemical inhibitors (LY294002, 
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Akti-1/2, and rapamycin, respectively) resulted in significant enhancement of HBV 
replication, as well as HBsAg and HBeAg secretion (Figure 4.10, A). In parallel, these 3 
inhibitors decreased phosphorylation of Akt, mTOR, and p70S6K, respectively, without 
significant affecting total expression levels of these proteins (Figure 4.10, B). Moreover, 
HepG2.215 cells were transfected with specific siRNAs against Akt, mTOR or control siR-C. 
As we expected, HBV replication, as well as HBsAg and HBeAg secretion (Figure 4.11, A), 
was significantly increased when Akt or mTOR expression was silenced (Figure 4.11, B). 
 
Figure 4.10 HBV replication is enhanced by inhibition of PI3K/Akt/mTOR signaling pathway 
(A) HepG2.2.15 cells were treated with medium, 1 µM of PI3K inhibitor LY294002, 1 µM of Akt inhibitor 
Akti-1/2, or 1 µM of mTOR inhibitor rapamycin for 72 h, and harvested at 72 h post the treatment of inhibitors. 
The detection of HBV replicative intermediates, secreted HBsAg and HBeAg in the supernatant was performed 
as described above. (B) Western blotting analysis was performed to detect the total and phosphorylated forms of 
the Akt, mTOR, and p70S6K proteins, using beta-actin as the loading control. S/CO = signal to cutoff ratio; RC, 
relaxed circular DNA; SS = single-stranded DNA. *, # P < 0.05; **, ## P < 0.01; ***, ### P < 0.001. 
 
 
Figure 4.11 HBV replication is enhanced by silencing of Akt or mTOR 
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HepG2.2.15 cells were transfected with specific siRNAs against Akt, mTOR or the siRNA control at 20 nM, and 
harvested after 96 h post transfection. (A) The detection of HBV replicative intermediates, secreted HBsAg and 
HBeAg in the supernatant was performed as described above. (B) Western blotting analysis was performed to 
detect the expression of Akt and mTOR proteins, and beta-actin was used as the loading control. S/CO = signal 
to cutoff ratio; RC, relaxed circular DNA; SS = single-stranded DNA. *, # P < 0.05; **, ## P < 0.01; ***, ### P 
< 0.001. 
 
4.3.3 The miR-99 family inhibits IGF-1R/PI3K/Akt/mTOR signaling pathway by 
directly targeting IGF-1R, Akt and mTOR 
Previous studies have identified the mRNA of IGF-1R, Akt, and mTOR as direct targets with 
binding sites for miR-99 family members (Figure 4.12).80, 82, 140-142 Thus, we tested whether 
ectopic expression of the miR-99 family could promote HBV replication by targeting the 
cellular IGF-1R/PI3K/Akt/mTOR signaling pathway. Firstly, we tested whether miR-99 
family members could regulate IGF-1R, Akt and mTOR functions in hepatoma cells. 
HepG2.2.15 cells were transfected with miR-99 family mimics at a final culture supernatant 
concentration of 40 nM for 72 h, and total and phosphorylated IGF-1R, Akt, mTOR, and 
p70S6K proteins were detected by western blotting. As shown in Figure 4.13, the miR-99 
family could significantly reduce the formation of total and phosphorylated forms of the 
IGF-1R, Akt, mTOR, and p70S6K proteins, in agreement with previous data obtained with 
other cell types.143 
 
Figure 4.12 The direct targeting of miR-99 family members 
MiR-99 family includes miR-100, miR-99a and miR-99b. They shared the same seed sequence and probably 
play a similar role in different cellular lives. They can directly target: IGF-1R, AKT1 and mTOR, and suppress 
their gene expression at post-transcriptional level. 
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Figure 4.13 The miR-99 family inhibits IGF-1R/PI3K/Akt/mTOR signaling pathway 
HepG2.2.15 cells were transfected with miR-99 family mimics or control miR-C at a final concentration of 40 
nM and harvested at 72 h post transfection. Western blotting analysis was performed to detect the total and 
phosphorylated protein of the IGF-1R, Akt, mTOR, and p70S6K proteins. 
 
4.3.4 The miR-99 family counteracts insulin-mediated activation of the 
PI3K/Akt/mTOR signaling pathway and downregulation of HBV replication 
Many growth factors, such as insulin and epithelial growth factor, promote activation of 
PI3K/Akt/mTOR signaling in hepatic and hepatocellular cells.144 Consistently, treatment of 
HepG2.2.15 cells with insulin at concentrations ranging from 1 to 10 μM for 72 h 
significantly reduced HBV replication in a dose-dependent manner (Figure 4.14). Compared 
to mock control with culture medium, insulin exposure also increased the levels of Akt and 
mTOR phosphorylation (Figure 4.15, A). 
 
Figure 4.14 Insulin inhibits HBV replication in different dose 
(A) HepG2.2.15 cells were treated with different doses of insulin (1, 5, and 10 µM) for 72 h. HBV RIs in cells 
were isolated and detected by Southern blotting. The levels of HBsAg and HBeAg in the supernatant were 
determined by chemiluminescent microparticle immunoassay. S/CO = signal to cutoff ratio; RC, relaxed circular 
DNA; SS = single-stranded DNA. * P < 0.05, ** P < 0.01, *** P < 0.001. 
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Figure 4.15 The miR-99 family counteracts insulin-mediated activation of the PI3K/Akt/mTOR signaling 
pathway and downregulation of HBV replication 
(A) HepG2.2.15 cells were pre-transfected with miR-99 family mimics or control miR-C at 40 nM. At 24 h 
post-transfection, fresh medium containing 5 µM insulin was added, and the cells were grown an additional 72 h. 
Western blotting analysis was performed to detect the total or phosphorylated levels of the Akt, mTOR, and 
p70S6K proteins using beta-actin as a loading control. (B) HBV replicative intermediates inside the cells were 
isolated and detected by Southern blotting. The levels of HBsAg and HBeAg in the supernatant were determined 
by chemiluminescent microparticle immunoassay. S/CO = signal to cutoff ratio; RC: relaxed circular DNA; SS = 
single-stranded DNA. *, # P < 0.05; **, ## P < 0.01; ***, ### P < 0.001. 
We investigated whether ectopic expression of miR-99 family members could inhibit the 
insulin-mediated activation of PI3K/Akt/mTOR signaling pathway and reverse the reduction 
of HBV replication. HepG2.2.15 cells were transfected with miR-99 family members at a 
final culture supernatant concentration of 40 nM. At 24 h post-transfection, the cells were 
exposed to insulin at a concentration of 10 μM for 72 h. Southern blotting analysis showed 
that treatment with insulin and miR-99 family members caused opposite effects on HBV 
replication and gene expression (Figure 4.15, B). Furthermore, ectopic expression of miR-99 
family promoted HBV replication, as well as HBsAg and HBeAg production in the presence 
of insulin. In contrast, the induction of Akt and mTOR phosphorylation by insulin was 
markedly reduced by miR-99 family members, and also causing a significant decrease in total 
Akt and mTOR protein expression, as shown by western blotting analysis (Figure 4.15, A). 
Altogether, these findings suggest that the miR-99 family members counteract 
insulin-mediated activation of the PI3K/Akt/mTOR signaling pathway and downregulation of 
HBV replication. 
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4.4 The miR-99 family promotes HBV replication through mTOR/ULK1 signaling 
pathway-induced complete autophagy 
4.4.1 The miR-99 family promotes HBV replication through mTOR/ULK1 signaling 
pathway-induced autophagy 
The Akt/mTOR signaling pathway is known to regulate several downstream processes 
including protein synthesis, ribosome biogenesis, lipid synthesis, nutrient import, and 
autophagy.94, 145, 146 To assess which biological process downstream of the Akt/mTOR 
signaling pathway may affect HBV replication, HepG2.2.15 cells were transfected with 6 
selected small interfering RNAs (siRNAs) at a final concentration of 20 nM targeting the 
downstream effectors of the Akt/mTOR signaling pathway. HBV replication and gene 
expression in HepG2.2.15 cells were analyzed at 96 h post transfection. Compared to the 
control, HBV replication, as well as HBsAg/HBeAg secretion significantly decreased 
following knockdown of ULK1 expression (Figure 4.16). These findings suggested that 
autophagy mediates, at least in part, the regulatory function of Akt/mTOR pathway on HBV 
replication, consistent with data from previous studies showing that autophagy played a major 
role in regulating HBV replication.87 
 
Figure 4.16 Knockdown of downstream genes of Akt/mTOR signaling affects HBV replication 
HepG2.2.15 cells were transfected with specific siRNAs against p70S6K, 4E-BP1, SREBP1, HIF-1α, ULK1, or 
IRF7 mRNAs, or a control siRNA (siR-C) at 20 nM, and harvested after 96 h. The levels of secreted HBsAg and 
HBeAg in the supernatant were determined by chemiluminescent microparticle immunoassay. HBV replicative 
intermediates inside the cells were isolated and detected by Southern blotting. S/CO = signal to cutoff ratio; RC: 
relaxed circular DNA; SS = single-stranded DNA. *, # P < 0.05; **, ## P < 0.01; ***, ### P < 0.001. 
Based on the results of the gene-silencing experiment, we asked whether the positive effect 
of miR-99 family members on HBV replication may be abolished by 3-MA, an inhibitor of 
autophagy. Consistent with previous findings, treatment with 3-MA alone significantly 
reduced HBsAg/HBeAg secretion, HBV replication, and capsid formation in HepG2.2.15 
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cells, but reverse results were obtained with rapamycin (Figure 4.17, A and B). The 
expression of green fluorescence protein (GFP) tagged LC3 was widely used to study 
autophagy. In this experiment, Huh7 cells were transfected with the GFP-LC3 plasmid, then 
treated with rapamycin or 3-MA, respectively. Indeed, rapamycin strongly promoted the 
formation of autophagic puncta, while 3-MA abolished it, as judged by using the 
immunofluorescence (IF) detection (Figure 4.17, C and D).  
 
Figure 4.17 Rapamycin and 3-MA modulate HBV replication and autophagy 
(A) HepG2.2.15 cells were treated with rapamycin at 1 µM or 3-MA at 10 mM for 48 h. The levels of secreted 
HBsAg and HBeAg in the supernatant were determined by chemiluminescent microparticle immunoassay. HBV 
replicative intermediates inside the cells were isolated and detected by Southern blotting. (B) The HBV capsids 
in cells were extracted and detected by western blotting, and beta-actin was used as the loading control. (C) 
Huh7 cells were transfected with the plasmid GFP-LC3, then treated with 100 nM rapamycin for 48 h or 10 mM 
3-MA for 24 h. Then the cells were fixed and stained with 6-diamidino-2-phenylindole (DAPI). (D) Statistical 
analysis of the number of LC3-dots per cell was performed. Bars, 5 µm. S/CO = signal to cutoff ratio; RC: 
relaxed circular DNA; SS = single-stranded DNA. *, # P < 0.05; **, ## P < 0.01; ***, ### P < 0.001. 
Thus, HepG2.2.15 cells were pre-transfected with 3 miR-99 family members or a control 
miRNA at a final concentration of 40 nM, and then treated with 3-MA for 48 h or MHY1485, 
an mTOR activator, for 72 h. Clearly, both the treatment of 3-MA (Figure 4.18, A) and 
MHY1485 (Figure 4.18, B) completely abolished the positive effect of the miR-99 family 
members on HBV replication. In contrast, treatment with rapamycin enhanced the effect of 
miR-99 family members on HBV replication in HepG2.2.15 cells (Figure 4.18, C). 
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Figure 4.18 Autophagic inhibitors affect the enhancing effect of miR-99 family on HBV replication 
HepG2.2.15 cells were pre-transfected with miR-99 family mimics or control miR-C at 40 nM, after which the 
cells were treated with 10 mM of 3-MA for 48 h (A), 1 µM of MHY1485 for 72 h (B), or 1 µM of rapamycin for 
72 h (C). The levels of secreted HBsAg and HBeAg in the supernatant were determined by chemiluminescent 
microparticle immunoassay. HBV replicative intermediates inside the cells were isolated and detected by 
Southern blotting. S/CO = signal to cutoff ratio; RC: relaxed circular DNA; SS = single-stranded DNA. * P < 
0.05, ** P < 0.01, *** P < 0.001. 
 
4.4.2 The miR-99 family induces complete autophagy formation 
Next, we examined whether miR-99 family members were indeed able to modulate 
autophagy in hepatoma cells. Interestingly, a recent report demonstrated that miR-100 could 
induce autophagy in HCC cells.143 Thus, HepG2.2.15 cells were transfected with miR-99 
family mimics or control miR-C and harvested after 72 h. Western blotting analysis confirmed 
that ectopic expression of the miR-99 family significantly elevated the level of autophagy 
marker LC3-II and promoted the degradation of cargo receptor SQSTM1/p62 (Figure 4.19, A 
and B).  
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Figure 4.19 The miR-99 family induces complete autophagy formation 
HepG2.2.15 cells were transfected with miR-99 family mimics or control miR-C at 40 nM and harvested after 72 
h. (A) The levels of LC3 and p62 expression were detected by western blotting, with beta-actin as a loading 
control. (B) The LC3-II/beta-actin ratios of western blotting bands were quantified by densitometric analysis 
using ImageJ software. * P < 0.05, ** P < 0.01, *** P < 0.001. 
 
Furthermore, Huh7 cells were cotransfected with 3 miR-99 family members or control 
miR-C and plasmid GFP-LC3, fixed, stained and finally subjected to confocal microscopy. In 
concordance with the western blotting results in HepG2.2.15 cells, the miR-99 family 
members strongly increased the formation of autophagic puncta in Huh7 cells (Figure 4.20, A 
and B).  
In addition, Huh7 cells were transfected with plasmid GFP-LC3 and miRNAs, and then 
treated with 10 μM chloroquine (CQ), an inhibitor that prevented the acidification of 
lysosomes. Just as our hypothesis, ectopic expression of miR-99 family members could 
further increase the formation of autophagosomes in Huh7 cells, as CQ reduced autophagic 
degradation and preserved the formed autophagosomes (Figure 4.20, C and D). Collectively, 
all 3 miR-99 family members were capable of promoting autophagy in hepatoma cells; 
therefore, they likely enhance HBV replication by promoting autophagy. 
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Figure 4.20 The miR-99 family promotes autophagosome formation 
Representative images of Huh7 cells co-transfected with the GFP-LC3 plasmid and miR-99 family mimics or 
control miR-C at 40 nM, and then followed without (A) or with 10 µM CQ for 24 h (C). The cells were fixed 
and stained with DAPI. Bars, 5 µm. (B and D) Statistical analysis of the numbers of LC3 puncta per cell were 
performed, respectively. RC, relaxed circular DNA; SS = single-stranded DNA. * P < 0.05, ** P < 0.01, *** P < 
0.001. 
 
4.4.3 HBV can be regulated through the mTOR/ULK1 signaling pathway 
As inhibition of mTOR activity led to the activation of autophagy via the 
ULK1-ATG13-FIP200 complex,94, 98, 147 we addressed the question whether the ULK1 
complex participate in miR-99 family-induced autophagy and enhancement of HBV 
replication. Firstly, we clarified the role of ULK1 on autophagic formation and HBV 
replication, as ULK1 plays a key role in the initiation of autophagosome formation.148 
HepG2.2.15 cells were transfected with miR-99 family mimics or control miR-C at a final 
concentration of 40 nM. Cell lysates were collected for western blotting analysis. We 
observed that ectopic expression of miR-99 family members resulted in ULK1 
dephosphorylation in hepatoma cells (Figure 4.21). However, ULK1 silencing by specific 
siRNAs abolished the enhancing effect of the miR-99 family members on HBV replication, 
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and HBsAg/HBeAg secretion (Figure 4.22), suggesting that ULK1 is required for the action 
of the miR-99 family on HBV replication and gene expression. 
 
Figure 4.21 MiR-99 family promotes the dephosphorylation of ULK1 
HepG2.2.15 cells were transfected with miR-99 family mimics or control miR-C at 40 nM and harvested after 72 
h. Total and phosphorylated ULK1 protein levels were detected by western blotting, using appropriate antibodies. 
Beta-actin was used as a loading control.  
 
 
Figure 4.22 HBV replication can be regulated through mTOR/ULK1 signaling pathway 
HepG2.2.15 cells were pre-transfected with specific siRNA against ULK1 or control siR-C at 20 nM. The cells 
were split into new 6-well plates at 24 h post-transfection. 24 hours later, the cells were transfected again with 
miR-99 family mimics or a miR-C control at 40 nM. HBV replicative intermediates inside the cells were isolated 
and detected by Southern blotting. The levels of HBsAg and HBeAg secretion in the supernatant were 
determined by chemiluminescent microparticle immunoassay. S/CO = signal to cutoff ratio; RC, relaxed circular 
DNA; SS = single-stranded DNA. *, # P < 0.05; **, ## P < 0.01; ***, ### P < 0.001. 
Next, we examined the consequences of silencing of ULK1, FIP200, and ATG13, 3 factors 
forming the complex for involved autophagy initiation, for HBV replication. Thus, 
HepG2.2.15 cells were transfected with specific siRNA against ULK1, FIP200, ATG13, ATG5 
or control siR-C at 20 nM, and harvested after 72 h. ATG5 was used as positive control, as it 
combined with ATG12 to form the ATG12 conjugation system and to regulate autophagic 
vesicle formation. The results revealed that the level of LC3-II expression significantly 
decreased, however, the degradation of p62 was blocked following silencing of these four 
targets (Figure 4.23, A and B). Meanwhile, the effectiveness of siRNA duplexes was verified 
by real-time RT-PCR (Figure 4.23, C).  
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Moreover, Huh7 cells were cotransfected with the GFP-LC3 plasmid and siRNAs, after 
which they were treated with 10 μM CQ for 24 h. Consistent with previous reports, we found 
that the frequencies of autophagic puncta of LC3 by confocal microscopy were significantly 
decreased by silencing of ULK1, FIP200, ATG13, or ATG5 (Figure 4.24, A and B). 
 
Figure 4.23 Silencing of ULK1-ATG13-FIP200 complex inhibits autophagy formation 
(A) HepG2.2.15 cells were transfected with specific siRNA against ULK1, FIP200, ATG13, ATG5 or control 
siR-C at 20 nM, and harvested after 72 h. The levels of LC3 and p62 expression were by western blotting, and 
beta-actin was used as a loading control. (B) The LC3-II/beta-actin ratios of western blotting bands were 
quantified by densitometric analysis using ImageJ software. (C) The levels of the corresponding mRNAs were 
determined by real-time RT-PCR using specific primers. * P < 0.05, ** P < 0.01, *** P < 0.001. 
We next sought to examine whether HBV replication was affected by silencing the 
components of the ULK1-ATG13-FIP200 complex. HepG2.2.15 cells were transfected with 
different specific siRNAs, and harvested at 96 h. As revealed in Figure 4.24 C, HBV 
replication, and HBsAg/HBeAg secretion into the supernatant were significantly decreased by 
knocking down ATG13 or ATG5 expression, however, the secretion of HBsAg and HBeAg 
was not significantly decreased by silencing of FIP200. Collectively, our data suggest that 
mTOR/ULK1 signaling pathway-induced complete autophagy is an important process that 
mediates the enhancing effect of miR-99 family members on HBV replication (Figure 4.25). 
Besides HBV, previous studies have shown that autophagy can be exploited by some other 
viruses, such as hepatitis C virus, dengue virus, and influenza A virus, to facilitate their 
replication.106, 107, 128, 129 However, the exact mechanisms of different phases of autophagic 
flux affecting virus production remain unclear. 
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Figure 4.24 HBV replication can be regulated through ULK1-ATG13-FIP200 complex 
(A) Representative images of Huh7 cells co-transfected with the plasmid GFP-LC3 and different specific 
siRNAs, and harvested after 48 h. The cells were fixed, and stained with DAPI. Bars, 5 µm. (B) Statistical 
analysis of the number of LC3 puncta per cell. (C) HepG2.2.15 cells were transfected with specific siRNAs 
against FIP200, ATG13, ATG5 or siRNA control at 20 nM, and harvested after 96 h. The detection of HBV 
replicative intermediates, secreted HBsAg and HBeAg in the supernatant was performed as described above. 
S/CO = signal to cutoff ratio; RC, relaxed circular DNA; SS = single-stranded DNA. * P < 0.05, ** P < 0.01, 
*** P < 0.001. 
 
 
Figure 4.25 Proposed model whereby miR-99 family members regulate HBV replication through 
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IGF-1R/PI3K/Akt/mTOR/ULK1 signaling-induced autophagy 
The miR-99 family members could decrease the levels of total and phosphorylated IGF-1R, Akt, and mTOR by 
directly targeting their mRNAs, and followed by ULK1 dephosphorylation, resulting in the initiation of 
autophagosome formation. Thus, ectopic expression of miR-99 family members could promote autophagosome 
formation through IGF-1R/PI3K/Akt/mTOR signaling pathway, and sequentially enhance HBV production. 
 
4.5 Different autophagic phases inversely affects HBV production  
4.5.1 Different autophagy inhibitors inversely affect HBV replication and HBsAg 
production 
To further the effect of different phases on HBV production, Huh7 cells were transfected with 
the GFP-LC3 plasmid, and treated with the lysosome inhibitor CQ and Rab7 inhibitor 
CID1067700 (CID) for 48 h, or the PI3KC3 inhibitor 3-MA for 24 h.130, 149 
Immunofluorescence microscopy showed that the number of GFP-LC3 puncta was obviously 
increased following treatment with CQ and CID, but decreased by 3-MA (Figure 4.26, A and 
B). Western blotting analysis of cellular lysates revealed that both CQ and CID dramatically 
stimulated the conversion of light chain 3 (LC3)-I to LC3-II, indicating an increase in 
membrane-associated LC3. Moreover, both CQ and CID elevated the levels of autophagic 
cargo SQSTM1/p62 and hepatitis B core antigen (HBcAg) in HepG2.2.15 cells (Figure 4.26, 
C). Interestingly, 3-MA elevated the levels of p62 expression, but decreased the levels of 
LC3-II and HBcAg. These results suggest that autophagy inhibitors act on different 
autophagic phases to have different effects on HBV production. 
To investigate the effects of different autophagy inhibitors on HBV production, analyses of 
secreted HBsAg, HBeAg and viral genomes from the supernatant, and intracellular HBsAg 
and viral genomes from the cell lysates were performed. Compared to control medium, the 
late autophagy inhibitors CQ and CID significantly increased the amount of secreted HBsAg 
and intracellular HBsAg as measured by chemiluminescent microparticle immunoassay 
(CMIA); however, 3-MA decreased their production (Figure 4.27, A and B). Further, the 
levels of HBV genomes in the supernatant and inside the cells determined by quantitative 
real-time PCR, and HBV replicative intermediates measured by Southern blotting were 
clearly increased (Figure 4.27, C and D).  
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Figure 4.26 Different autophagy inhibitors affect autophagy process 
(A) Huh7 cells were transfected with the green fluorescence protein (GFP)-LC3 plasmid (green), followed 
by treatment with autophagy inhibitors, 10 µM chloroquine (CQ) and 5 µM CID1067700 (CID) for 48 h, 
and 10 mM 3-MA for 24 h. The cells were fixed and stained with 6-diamidino-2-phenylindole (DAPI, blue). 
Bars, 5 µm. (B) Statistical analysis of the number of LC3 puncta per cell. (C) HepG2.2.15 cells were 
treated with autophagy inhibitors, 10 µM CQ and 5 µM CID for 48 h, and 10 mM 3-MA for 24 h. LC3, p62, 
and HBcAg expression was analyzed by western blotting. Beta-actin was used as a loading control. S/CO = 
signal to cutoff ratio; RC: relaxed circular DNA; SS = single-stranded DNA. * P < 0.05, ** P < 0.01, *** P 
< 0.001. 
Moreover, the effects of different autophagy inhibitors on HBV production were detected 
in primary hepatocytes (PHHs). Western blotting showed that the levels of LC3-II expression 
were significantly elevated by late autophagy inhibitors CQ and CID in PHHs with HBV 
infection (Figure 4.28, A), but decreased by early autophagy inhibitors 3-MA. Analysis of 
secreted HBsAg and intracellular HBsAg showed that both CQ and CID significantly 
increased HBsAg production in PHHs; however, 3-MA decreased HBsAg production (Figure 
4.28, B and C).  
As the promotion of HBV replication may be mediated by its transcription, the effect of 
different autophagy inhibitors on HBV transcription was evaluated by real-time RT-PCR. 
Strikingly, quantification of HBV RNA revealed that all the autophagy inhibitors CQ, CID, 
and 3-MA did not affect the levels of HBV RNA in HepG2.2.15 cells, indicating that 
inhibition of different autophagic phases did not inhibit HBV transcription (Figure 4.29, A). 
In addition, the effect of different autophagy inhibitors on the activities of HBV promoters 
was measured by Dual-Glo luciferase report assays. Consistently, we observed that the 
luciferase activities of the HBV SP1, SP2, Core, and X promoters were not clearly changed 
by all the autophagy inhibitors (Figure 4.29, B). 
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These data demonstrate that inhibition of different autophagic phases using various 
autophagy inhibitors may inversely affect HBV replication and HBsAg production. 
 
Figure 4.27 Different autophagy inhibitors affect HBV production in Hep2.2.15 cells 
HepG2.2.15 cells were treated with autophagy inhibitors, 10 µM chloroquine (CQ) and 5 µM CID1067700 
(CID) for 48 h, and 10 mM 3-MA for 24 h. (A) Analysis of secreted HBsAg and HBeAg from the 
supernatant and intracellular HBsAg from cell lysates was performed by chemiluminescent microparticle 
immunoassay. (B) The graph shows the relative values of HBsAg from the supernatant and cell lysates. (C) 
The levels of HBV genomes in the supernatant and inside the cells were determined by quantitative 
real-time polymerase chain reaction. Hepatitis B virus replicative intermediates inside the cells were 
isolated and measured by Southern blotting. (D) The graph shows the relative values of secreted and 
intracellular viral genomes. S/CO = signal to cutoff ratio; RC: relaxed circular DNA; SS = single stranded 
DNA. *, # P < 0.05; **, ## P < 0.01; ***, ### P < 0.001. 
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Figure 4.28 Different autophagy inhibitors affect HBV production in primary hepatocytes 
Primary hepatocytes with HBV infection were treated with the autophagy inhibitors, 10 µM CQ and 5 µM 
CID for 48 h, and 10 mM 3-MA for 24 h. (A) LC3 and p62 expression was analyzed by western blotting, 
with beta-actin used as a loading control. (B) Analysis of secreted HBsAg and HBeAg in the supernatant 
and intracellular HBsAg from cell lysates in HBV-infected PHHs was performed by chemiluminescent 
microparticle immunoassay. (C) The graph shows the relative values of HBsAg from the supernatant and 
cell lysates. S/CO = signal to cutoff ratio. * P < 0.05, ** P < 0.01, *** P < 0.001. 
 
 
Figure 4.29 Different autophagy inhibitors affect HBV transcription and promoter activity 
(A) HepG2.2.15 cells were treated with autophagy inhibitors, 10 µM chloroquine (CQ) and 5 µM 
CID1067700 (CID) for 48 h, and 10 mM 3-MA for 24 h. HBV pregenomic RNA (pgRNA) levels were 
analyzed by real-time reverse transcriptase polymerase chain reaction using primers specific for the 
pgRNA-specific region. (B) Huh7 cells were transfected with luciferase reporters containing the HBV 
promoter regions pSP1, pSP2, pCP, and pXP, and Renilla as an internal control for 48 h. Firefly and Renilla 
luciferase activities were analyzed by Dual-Glo luciferase reporter assay. Relative luciferase expression 
was calculated by fold-change and normalized to control medium treated samples. 
 
4.5.2 Silencing of Rab5 decreases HBV replication and HBsAg production 
Rab5, a member of the small GTPase family, has been demonstrated to play an important role 
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in autophagy and is crucial for HCV replication.114 Thus, we investigated whether silencing of 
Rab5 could regulate autophagosome formation in hepatoma cells. First, immunofluorescence 
microscopy showed that silencing of Rab5 decreased the number of GFP-LC3 puncta (Figure 
4.30, A and B). Western blotting analysis of cellular lysates confirmed that silencing of Rab5 
decreased the levels of LC3-II using specific siRNA compared to the siRNA control in Huh7 
cells; however, the autophagic cargo receptor p62 and HBcAg were increased (Figure 4.30, 
C). Strikingly, decreased expression of Rab5 strongly decreased the amount of HBV capsid 
and capsid-associated HBV DNA detected by western blotting and Southern blotting analyses, 
respectively. These results suggest that silencing of Rab5 decrease HBV production by 
inhibiting the formation of early autophagy.  
 
Figure 4.30 Silencing of Rab5 blocks autophagy formation 
(A) Huh7 cells were cotransfected with GFP-LC3 plasmid (green) and specific small interfering RNAs against 
Rab5 (siRab5) or control siRNA (siR-C) at 20 nM and harvested after 48 h. The cells were fixed and stained with 
DAPI (blue). (B) Statistical analysis of the number of LC3 puncta per cell. (C) Huh7 cells were cotransfected 
with pSM2 plasmid and specific siRab5 or control siRNA (siR-C) at 20 nM and harvested after 72 h. Analysis of 
encapsidated HBV DNA was performed by Southern blotting. Rab5, LC3, p62, HBcAg, and viral nucleocapsid 
expression was analyzed by western blotting. Beta-actin was used as a loading control. S/CO = signal to cutoff 
ratio. * P < 0.05, ** P < 0.01, *** P < 0.001. 
  To confirm that silencing of Rab5 decreases the levels of secreted and intracellular HBV 
production, secreted HBsAg and HBeAg in the supernatant and intracellular HBsAg from cell 
lysates were quantified by CMIA in Huh7 cells. The results revealed that silencing of Rab5 
obviously decreased the levels of secreted HBsAg in the supernatant and intracellular HBsAg, 
but there was no significant effect on secreted HBeAg (Figure 4.31, A and B). Quantification 
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of HBV DNA by quantitative real-time PCR revealed that silencing of Rab5 significantly 
decreased the levels of intracellular HBV DNA in Huh7 cells. Moreover, Southern blotting 
confirmed that silencing of Rab5 decreased HBV replication (Figure 4.31, C and D). 
Next, we examined the consequences of silencing Rab5 on HBV replication in HepG2.2.15 
cells. The cells were transfected with specific siRab5 and harvested after 96 h. In concordance 
with the results of HBsAg in Huh7 cells, the results showed that silencing of Rab5 obviously 
decreased the levels of secreted HBsAg in the supernatant and intracellular HBsAg, but there 
was no significant effect on secreted HBeAg (Figure 4.32, A and B). Quantification of HBV 
DNA by quantitative real-time PCR revealed that silencing of Rab5 significantly decreased 
HBV DNA in the supernatant and inside the cells. Moreover, Southern blotting analysis 
confirmed that silencing of Rab5 decreased HBV replicative intermediates (Figure 4.32, C 
and D). 
 
Figure 4.31 Silencing of Rab5 decreases HBV production in Huh7 cells 
Huh7 cells were cotransfected with pSM2 plasmid and specific siRab5 or control siRNA (siR-C) at 20 nM and 
harvested after 72 h. (A) Analysis of secreted HBsAg and HBeAg in the supernatant and intracellular HBsAg 
from cell lysates was performed by chemiluminescent microparticle immunoassay. (B) The graph shows the 
relative values of HBsAg from the supernatant and cell lysates. (C) The levels of HBV genomes inside the cells 
were determined by quantitative real-time polymerase chain reaction. Analysis of HBV replicative intermediates 
was performed by Southern blotting. (D) The graph shows the relative values of intracellular viral genomes. 
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S/CO = signal to cutoff ratio; RC: relaxed circular DNA; SS = single-stranded DNA. * P < 0.05, ** P < 0.01, 
*** P < 0.001. 
 
 
Figure 4.32 Silencing of Rab5 decreases HBV production in HepG2.2.15 cells 
HepG2.2.15 cells were transfected with specific siRab5 or control siRNA (siR-C) at 20 nM and harvested after 
96 h. (A) Analysis of secreted HBsAg and HBeAg in the supernatant and intracellular HBsAg from cell lysates 
was performed by chemiluminescent microparticle immunoassay. (B) The graph shows the relative values of 
HBsAg from the supernatant and cell lysates. (C) The levels of HBV genomes inside the cells were determined 
by quantitative real-time polymerase chain reaction. Analysis of HBV replicative intermediates was performed 
by Southern blotting. (D) The graph shows the relative values of secreted and intracellular viral genomes. S/CO 
= signal to cutoff ratio; RC: relaxed circular DNA; SS = single-stranded DNA. * P < 0.05, ** P < 0.01, *** P < 
0.001. 
Moreover, we test the consequences of silencing of Rab5 in different HBsAg expressive 
abundance. Huh7 cells were cotransfected with an expression vector with HBsAg high 
expression (HK-188) or with HBsAg low expression (HBs-2-S), and specific siRab5 or 
control siRNA. The results revealed that silencing of Rab5 obviously decreased the levels of 
secreted HBsAg in the supernatant and intracellular HBsAg from cell lysates with HBsAg 
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low expression (Figure 4.33, A and B), but there was no significant effect on HBsAg high 
expression (Figure 4.33, C and D). These data confirm that silencing of Rab5 leads to 
different consequences of HBsAg production in different HBsAg expressive abundance. 
As the promotion of HBV replication may be mediated by its transcription, the effect of 
silencing of Rab5 on HBV transcription was evaluated by real-time RT-PCR. Strikingly, 
quantification of HBV RNA revealed that silencing of Rab5 did not affect the levels of HBV 
RNA in HepG2.2.15 cells, indicating that silencing of Rab5 did not inhibit HBV transcription 
(Figure 4.34, A). In addition, the effect of silencing of Rab5 on the activities of HBV 
promoters was measured by Dual-Glo luciferase report assays. Consistently, we observed that 
the luciferase activities of the HBV SP1, SP2, Core, and X promoters were not clearly 
changed by silencing of Rab5 (Figure 4.34, B). These data suggest that silencing of Rab5 
decrease HBV production neither through inhibiting HBV transcription nor through inhibiting 
HBV promoter activities. 
Taken together, these data demonstrate that silencing of Rab5 decreases the amount of 
secreted and intracellular HBsAg, as well as the levels of secreted HBV DNA and 
intracellular HBV replication. 
 
Figure 4.33 Silencing of Rab5 affects HBsAg production in different HBsAg expressive abundance 
Huh7 cells were cotransfected with an expression vector (A) with HBsAg low expression (HBs-2-S) or (C) with 
HBsAg high expression (HK-188), and specific siRab5 or control siRNA (siR-C) at 20 nM, and harvested after 
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72 h. Secreted HBsAg in the supernatant and intracellular HBsAg from cell lysates were analyzed by 
chemiluminescent microparticle immunoassay. (B and D) The graphs show the relative values of HBsAg from 
the supernatant and cell lysates. * P < 0.05; ** P < 0.01; *** P < 0.001. 
 
 
Figure 4.34 Silencing of Rab5 does not inhibit HBV transcription and promoter activity 
HepG2.2.15 cells were transfected with specific siRab5 or control siRNA (siR-C) at 20 nM and harvested after 
72 h. (A) Analysis of HBV pregenomic RNA (pgRNA) levels was performed by real-time reverse transcriptase 
polymerase chain reaction, using primers specific for the pgRNA-specific region. (B) Luciferase reporters 
containing the HBV promoter regions pSP1, pSP2, pCP, and pXP were co-transfected with specific siRab5 or 
control siRNA (siR-C) at 20 nM into Huh7 cells. At 48 h post-transfection, firefly and Renilla luciferase 
activities were analyzed by Dual-Glo luciferase report assay. Relative luciferase expression was calculated by 
fold-change, and normalized to control medium treated samples. 
 
4.5.3 Activation of Rab5 promotes HBV replication and HBsAg production 
To clarify the effect of Rab5 on autophagosome formation, Huh7 cells were cotransfected 
with GFP-LC3 plasmid and an expression vector carrying Rab5 (Flag-Rab5) or control vector 
(pcDNA5), and GFP-LC3 puncta were detected by immunofluorescence microscopy. The 
results revealed that overexpression of Rab5 increased the number of GFP-LC3 puncta 
(Figure 4.35, A and B). Western blotting analysis confirmed that overexpression of Rab5 
dramatically stimulated the conversion of LC3-I to LC3-II, but decreased the levels of 
autophagic cargo p62 and HBcAg (Figure 4.35, C). 
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Figure 4.35 Overexpression of Rab5 promotes autophagy formation 
(A) Huh7 cells were cotransfected with GFP-LC3 plasmid (green) and an expression vector carrying Rab5 
(Flag-Rab5) or control vector (pcDNA5) and harvested after 48 h. The cells were fixed, incubated with primary 
antibody anti-HA, and then stained with Alexa Fluor 594 (red) conjugated anti-rabbit secondary antibody IgG. (B) 
Statistical analysis of the number of GFP-LC3 puncta per cell. (C) Huh7 cells were cotransfected with pSM2 
plasmid and Flag-Rab5 or control vector pcDNA5 and harvested after 72 h. Analysis of encapsidated HBV DNA 
was performed by Southern blotting. Rab5, LC3, p62, HBcAg, and viral nucleocapsid expression was analyzed 
by western blotting, with beta-actin used as a loading control. * P < 0.05; ** P < 0.01; *** P < 0.001. 
Because previous studies demonstrated that Rab5 is crucial for HCV replication, we 
examined the effect of Rab5 on HBV formation. As expected, overexpression of Rab5 
strongly increased HBV capsid according to western blotting, and capsid-associated HBV 
DNA according to Southern blotting analysis in Huh7 cells (Figure 2.10, C). Furthermore, the 
results of CMIA revealed that overexpression of Rab5 clearly increased secreted HBsAg 
levels in the supernatant and intracellular HBsAg, but there was no significant effect on 
secreted HBeAg (Figure 4.36, A and B). Quantification of HBV DNA by quantitative 
real-time PCR revealed that overexpression of Rab5 significantly increased the levels of 
intracellular HBV DNA. In addition, Southern blotting analysis confirmed that 
overexpression of Rab5 enhanced HBV replication (Figure 4.36, C and D). 
Next, we examined the effect of defective activation of Rab5 on HBV replication. Huh7 
cells were cotransfected with the pSM2 plasmid and an expression vector carrying 
constitutively active Rab5 (Rab5 CA), dominant negative Rab5 (Rab5 DN), or control vector 
pEGFP-N1, and harvested after 72 h. Secreted HBsAg and HBeAg in the supernatant and 
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intracellular HBsAg from cell lysates were quantified as described above. The results revealed 
that overexpression of mutant Rab5 clearly decreased the levels of secreted HBsAg in the 
supernatant and intracellular HBsAg; however, overexpression of constitutively active Rab5 
strongly increased their relative expression (Figure 4.37, A and B). Quantification of HBV 
DNA by quantitative real-time PCR revealed that overexpression of mutant Rab5 
significantly decreased intracellular HBV DNA levels in Huh7 cells. In addition, Southern 
blotting analysis confirmed that overexpression of mutant Rab5 decreased the levels of HBV 
replication (Figure 4.37, C and D). 
Taken together, these data reveal that activation of Rab5 increased the amount of secreted 
and intracellular HBsAg, as well as secreted HBV DNA levels and intracellular HBV 
replication. 
 
Figure 4.36 Overexpression of Rab5 increases HBV production 
(A) Huh7 cells were cotransfected with pSM2 plasmid and Flag-Rab5 or control vector pcDNA5 and harvested 
after 72 h. Analysis of encapsidated HBV DNA was performed by Southern blotting. Rab5, LC3, p62, HBcAg, 
and viral nucleocapsid expression was performed by western blotting, with beta-actin as a loading control. (B) 
The levels of secreted HBsAg and HBeAg in the supernatant and intracellular HBsAg from cell lysates were 
detected by CMIA. (C) The graph shows the relative values of HBsAg from the supernatant and cell lysates. The 
levels of HBV genomes inside the cells were detected by quantitative real-time PCR analysis. Analysis of HBV 
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replicative intermediates was performed by Southern blotting. (D) The graph shows the relative values of 
intracellular viral genomes. S/CO = signal to cutoff ratio; RC: relaxed circular DNA; SS = single-stranded DNA. 
*, # P < 0.05; **, ## P < 0.01; ***, ### P < 0.001. 
 
 
Figure 4.37 Activation of Rab5 increases HBV production 
Huh7 cells were cotransfected with pSM2 plasmid and an expression vector carrying constitutively active Rab5 
(Rab5 CA), dominant negative Rab5 (Rab5 DN), or control vector pEGFP-N1 and harvested after 72 h. (A) 
Analysis of secreted HBsAg and HBeAg in the supernatant and intracellular HBsAg from cell lysates was 
performed by chemiluminescent microparticle immunoassay. (B) The graph shows the relative values of HBsAg 
from the supernatant and cell lysates. (C) The levels of HBV genomes inside the cells were determined by 
quantitative real-time polymerase chain reaction. Analysis of HBV replicative intermediates was performed by 
Southern blotting. (D) The graph shows the relative values of secreted and intracellular viral genomes. S/CO = 
signal to cutoff ratio; RC: relaxed circular DNA; SS = single-stranded DNA. * P < 0.05; ** P < 0.01; *** P < 
0.001. 
 
4.5.4 Silencing of Rab5 decreases HBV production by interfering with autophagosome 
formation 
To determine the exact mechanism of Rab5 affecting HBV formation, we analyzed the effect 
of inhibiting early autophagic phase on autophagosome formation. Colocalization of 
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GFP-LC3 with HBs-Cherry was evaluated by confocal microscopy in Huh7 cells. First, the 
results showed that knockdown of Rab5 decreased the number of GFP-LC3 puncta (Figure 
4.38, A and B). Further confocal microscopy analysis showed that silencing of Rab5 slightly 
decreased the colocalization of GFP-LC3 with HBs-Cherry, while treatment with CQ strongly 
increased colocalization. These data indicate that inhibition of autophagosome formation by 
silencing of Rab5 decreased intracellular HBsAg. 
 
Figure 4.38 Silencing of Rab5 decreases the colocalization of LC3 and HBsAg 
(A) Huh7 cells were transfected with HBsAg plasmid with expressing mCherry (red). At 24 h post-transfection, 
the cells were split and cotransfected with GFP-LC3 plasmid (green) and specific siRab5 or control siRNA 
(siR-C) at 20 nM and harvested after 48 h. The cells were fixed and stained with DAPI (blue). The colocalization 
of LC3 and HBsAg was measured by confocal microscopy. Bars, 5 µm. (B) Statistical analysis of the 
colocalization coefficient of LC3 and HBsAg. * P < 0.05, ** P < 0.01, *** P < 0.001. 
The results were further confirmed by silencing of ULK1 or Rab5, followed by treatment 
with rapamycin or 3-MA. Quantification of secreted HBsAg in the supernatant and 
intracellular HBsAg from cell lysates revealed that rapamycin further increased the levels of 
secreted and intracellular HBsAg in HepG2.2.15 cells, but did not significantly increase 
following silencing of ULK1 (Fig. 4.39) or Rab5 (Fig. 4.40). However, 3-MA further 
decreased the levels of secreted and intracellular HBsAg, with no significant difference 
following silencing of Rab5 compared to the siRNA control. Thus, these data indicate that 
silencing of Rab5 decreases the levels of secreted and intracellular HBsAg by blocking the 
autophagosome formation. 
Taken together, these data demonstrate that silencing of Rab5 decreases HBV production 
and secretion by interfering with autophagosome formation. 
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Figure 4.39 Silencing of ULK1 decreases HBV production by interfering with early autophagy 
HepG2.2.15 cells were transfected with specific siULK1 or control siRNA (siR-C) at 20 nM. At 24 h 
post-transfection, the cells were treated with 2 µM rapamycin (Rapa), or 10 mM 3-MA for 48 h. The levels of 
secreted HBsAg and HBeAg in the supernatant and intracellular HBsAg from cell lysates were determined by 
chemiluminescent microparticle immunoassay. S/CO = signal to cutoff ratio. *, # P < 0.05; **, ## P < 0.01; ***, 
### P < 0.001; ns, not significant. 
 
 
Figure 4.40 Silencing of Rab5 decreases HBV production by interfering with early autophagy 
HepG2.2.15 cells were transfected with specific siRab5 or control siRNA (siR-C) at 20 nM. At 24 h 
post-transfection, the cells were treated with 2 µM rapamycin (Rapa) or 10 mM 3-MA for 48 h. The levels of 
secreted HBsAg and HBeAg in the supernatant and intracellular HBsAg from cell lysates were determined by 
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chemiluminescent microparticle immunoassay. S/CO = signal to cutoff ratio. *, # P < 0.05; **, ## P < 0.01; ***, 
### P < 0.001; ns, not significant. 
 
4.5.5 Silencing of Rab7 promotes HBV replication and HBsAg production 
HBV is known to hijack steps of the autophagic pathway by inhibiting autophagic 
degradation through impairing lysosomal maturation or dampening autophagy maturation via 
negative regulation of Rab7 expression. During the maturation process of EEs, inactivated 
Rab5 is substituted by Rab7 on the endosomal membrane. Subsequently, Rab7 may recruit its 
effectors, RILP and OSBPL1A/ORP1L, followed by directing the LE trafficking and 
participating in the fusion step with lysosomes. Thus, we investigated whether autophagic 
degradation of autophagosome -lysosome fusion is the major target of HBV. 
We observed that silencing of Rab7 increased the number of GFP-LC3 puncta by 
immunofluorescence microscopy in Huh7 cells (Figure 4.41, A and B). Western blotting 
analysis of cellular lysates confirmed that silencing of Rab7 elevated the levels of autophagic 
cargo LC3-II and p62 by specific siRab7 compared to the siRNA control (Figure 4.41, C). As 
expected, decreased expression of Rab7 strongly increased HBcAg and HBV capsid levels 
detected by western blotting, and increased the levels of capsid-associated HBV DNA 
detected by Southern blotting analysis. These data demonstrate that silencing of Rab7 
promotes HBV production by modulating the autophagosome-lysosome fusion process. 
 
Figure 4.41 Silencing of Rab7 blocks the degradation of autophogosomes 
Huh7 cells were cotransfected with GFP-LC3 plasmid (green) and specific small interfering RNAs against Rab7 
(siRab7) or control siRNA (siR-C) at 20 nM and harvested after 48 h. (A) The cells were fixed and stained with 
DAPI (blue). The GFP-LC3 puncta were measured by confocal microscopy. Bars, 5 µm. (B) Statistical analysis 
of the number of LC3 puncta per cell. (C) Huh7 cells were cotransfected with pSM2 plasmid and specific siRab7 
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or control siRNA (siR-C) at 20 nM and harvested after 72 h. Analysis of encapsidated HBV DNA was performed 
by Southern blotting. Rab7, LC3, p62, HBcAg, and viral nucleocapsid expression was analyzed by western 
blotting. Beta-actin was used as a loading control. * P < 0.05, ** P < 0.01, *** P < 0.001. 
  It was previously reported that CID is a potent Rab7 inhibitor; thus, we evaluated its effect 
on HBV replication in HepG2.2.15 cells. In the present study, CID treatment led to an 
increase in secreted HBsAg and HBV replicative intermediates (Figure 4.42). As we 
hypothesized, silencing of Rab7 increased the levels of secreted and intracellular HBV. CMIA 
analysis revealed that silencing of Rab7 strongly increased the levels of secreted HBsAg in 
the supernatant and intracellular HBsAg, but there was no significant effect on secreted 
HBeAg (Figure 4.43, A and B). Moreover, silencing of Rab7 increased intracellular HBV 
DNA levels according to quantitative real-time PCR and HBV replicative intermediates 
according to Southern blotting analysis (Figure 4.43, C and D). 
Next, we sought to confirm that knockdown of Rab7 affects HBV replication in 
HepG2.2.15 cells. The cells were transfected with specific siRab7 and harvested after 96 h. In 
concordance with the previous results in Huh7 cells, the data revealed that silencing of Rab7 
clearly increased the levels of secreted HBsAg in the supernatant and intracellular HBsAg 
(Figure 4.44, A and B). Quantification of HBV DNA by quantitative real-time PCR revealed 
that silencing of Rab7 significantly increased the levels of HBV DNA in the supernatant and 
inside of the cells. Moreover, Southern blotting analysis further confirmed that silencing of 
Rab7 promoted HBV replication (Figure 4.44, C and D). 
Moreover, we test the consequences of silencing of Rab7 in different HBsAg expressive 
abundance. Huh7 cells were cotransfected with an expression vector with HK-188 or HBs-2-S, 
and specific siRab7 or control siRNA. The results revealed that silencing of Rab7 obviously 
increased the levels of secreted HBsAg in the supernatant and intracellular HBsAg from cell 
lysates with HBsAg low expression (Figure 4.45, A and B). Silencing of Rab7 also 
significantly increased intracellular HBsAg levels with HBsAg high expression, but there was 
no significant effect on secreted HBsAg (Figure 4.45, C and D). These results confirm that 
silencing of Rab7 leads to different consequences of HBsAg production in different HBsAg 
expressive abundance. 
Finally, the effect of silencing of Rab7 on HBV transcription was evaluated by real-time 
RT-PCR. The results showed that silencing of Rab7 did not affect HBV RNA levels in 
HepG2.2.15 cells (Figure 4.46, A). In addition, the effect of silencing of Rab7 on the activities 
of HBV promoters was measured by Dual-Glo luciferase report assays. Consistently, we 
observed that the luciferase activities of the HBV SP1, SP2, Core, and X promoters were not 
significantly changed by silencing of Rab7 (Figure 4.46, B). These data suggest that silencing 
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of the Rab7 increase HBV production neither through promoting HBV transcription nor 
through promoting HBV promoter activities. 
These data demonstrate that silencing of Rab7 increases secreted and intracellular HBsAg 
levels, as well as secreted HBV DNA levels and intracellular HBV replication. 
 
Figure 4.42 Rab7 inhibitor increases HBV production in different dose 
HepG2.2.15 cells were treated with different doses of CID1067700 (CID, 0, 2 μM, or 5 μM) and harvested after 
48 h. Analysis of HBV replicative intermediates was performed by Southern blotting. Analysis of secreted 
HBsAg and HBeAg in the supernatant and intracellular HBsAg from cell lysates was performed by 
chemiluminescent microparticle immunoassay. S/CO = signal to cutoff ratio; RC: relaxed circular DNA; SS = 
single-stranded DNA. *, # P < 0.05; **, ## P < 0.01; ***, ### P < 0.001. 
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Figure 4.43 Silencing of Rab7 promotes HBV replication and HBsAg production in Huh7 cells 
Huh7 cells were cotransfected with pSM2 plasmid and specific siRab7 or control siRNA (siR-C) at 20 nM and 
harvested after 72 h. (A) Analysis of secreted HBsAg and HBeAg in the supernatant and intracellular HBsAg 
from cell lysates was performed by chemiluminescent microparticle immunoassay. (B) The graph shows the 
relative values of HBsAg from the supernatant and cell lysates. (C) The levels of HBV genomes inside the cells 
were determined by quantitative real-time polymerase chain reaction. Analysis of HBV replicative intermediates 
was performed by Southern blotting. (D) The graph shows the relative values of intracellular viral genomes. 
S/CO = signal to cutoff ratio; RC: relaxed circular DNA; SS = single-stranded DNA. * P < 0.05; ** P < 0.01; 
*** P < 0.001. 
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Figure 4.44 Silencing of Rab7 promotes HBV replication and HBsAg production in HepG2.2.15 cells 
HepG2.2.15 cells were transfected with specific siRab7 or control siRNA (siR-C) at 20 nM and harvested after 
96 h. (A) Analysis of secreted HBsAg and HBeAg in the supernatant and intracellular HBsAg from cell lysates 
was performed by chemiluminescent microparticle immunoassay. (B) The graph shows the relative values of 
HBsAg from the supernatant and cell lysates. (C) The levels of HBV genomes inside the cells were determined 
by quantitative real-time polymerase chain reaction. Analysis of HBV replicative intermediates was performed 
by Southern blotting. (D) The graph shows the relative values of secreted and intracellular viral genomes. S/CO 
= signal to cutoff ratio; RC: relaxed circular DNA; SS = single-stranded DNA. *, # P < 0.05; **, ## P < 0.01; 
***, ### P < 0.001. 
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Figure 4.45 Silencing of Rab7 affects HBsAg production in different HBsAg expressive abundance 
Huh7 cells were cotransfected with an expression vector with (A) with HBsAg low expression (HBs-2-S) or (C) 
HBsAg high expression (HK-188), and specific siRab7 or control siRNA (siR-C) at 20 nM, and harvested after 
72 h. Secreted HBsAg in the supernatant and intracellular HBsAg from cell lysates were analyzed by 
chemiluminescent microparticle immunoassay. (B and D) The graphs show the relative values of HBsAg from 
the supernatant and cell lysates. * P < 0.05; ** P < 0.01; *** P < 0.001. 
 
 
Figure 4.46 Silencing of Rab7 does not promote HBV transcription and promoter activity 
HepG2.2.15 cells were transfected with specific siRab7 or control siRNA (siR-C) at 20 nM and harvested after 
72 h. (A) Analysis of HBV pregenomic RNA (pgRNA) levels was performed by real-time reverse transcriptase 
polymerase chain reaction, using primers specific for the pgRNA-specific region. (B) Luciferase reporters 
containing the HBV promoter regions pSP1, pSP2, pCP, and pXP were co-transfected with specific siRab7 or 
control siRNA (siR-C) at 20 nM into Huh7 cells. At 48 h post-transfection, firefly and Renilla luciferase 
activities were analyzed by Dual-Glo luciferase report assay. The relative luciferase expression was calculated by 
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fold-change, and normalized to control medium treated samples. S/CO = signal to cutoff ratio. *, # P < 0.05; **, 
## P < 0.01; ***, ### P < 0.001. 
 
4.5.6 Activation of Rab7 inhibits HBV replication and HBsAg production 
To investigate the effect of Rab7 activation on autophagosome formation, Huh7 cells were 
cotransfected with the GFP-LC3 plasmid and an expression vector carrying wild-type Rab7 
(Rab7 WT), dominant negative Rab7 (Rab7 DN), or control vector pEGFP-N1, and harvested 
at 48 h. The puncta of internal LC3 were measured by immunofluorescence microscopy. The 
results revealed that overexpression of wild-type Rab7 increased the number of GFP-LC3 
puncta (Figure 4.47, A and B), but decreased following inactivation of Rab7 with the Rab7 
DN plasmid. Western blotting analysis confirmed that overexpression of Rab7 dramatically 
degraded the autophagic cargo LC3-II and p62 and decreased the levels of HBcAg (Figure 
4.47, C).  
 
Figure 4.47 Activation of Rab7 promotes autophagic degradation 
Huh7 cells were transfected with an expression vector carrying wild type Rab7 (Rab7 WT), dominant negative 
Rab7 (Rab7 DN) or control vector (pEGFP-N1) and harvested after 48 h. The cells were fixed, incubated with 
anti-LC3, and then stained with Alexa Fluor 594 (red) - conjugated anti-rabbit secondary antibody IgG. The 
nuclei were stained with DAPI (blue). Rab7 is visualized in green. (A) The GFP-LC3 puncta were measured by 
confocal microscopy. Bars, 5 µm. (B) Statistical analysis of the number of GFP-LC3 puncta per cell. (C) Huh7 
cells were cotransfected with pSM2 plasmid and Rab7 WT, Rab7 DN, or control vector pEGFP-N1 and 
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harvested after 72 h. Analysis of encapsidated HBV DNA was performed by Southern blotting. LC3, p62, 
HBcAg, and viral nucleocapsid expression was analyzed by western blotting, with beta-actin as a loading control. 
* P < 0.05; ** P < 0.01; *** P < 0.001. 
As Rab7 has different functions in vehicle transport and is particularly an essential 
component of autophagosome-lysosome fusion, we tested the effect of Rab7 on HBV 
formation in Huh7 cells. The data showed that activation of Rab7 decreased the amount of 
HBV capsid detected by western blotting and increased the levels of capsid-associated HBV 
DNA detected by Southern blotting analysis. Moreover, activation of Rab7 clearly decreased 
the levels of secreted HBsAg in the supernatant and intracellular HBsAg (Figure 4.48, A and 
B). Quantitative real-time PCR analysis revealed that activation of Rab7 decreased 
intracellular HBV DNA levels. In addition, Southern blotting analysis confirmed that 
activation of Rab7 inhibited HBV replicative intermediates (Figure 4.48, C and D). 
Collectively, these data reveal that activation of Rab7 decreased the amount of secreted and 
intracellular HBsAg, as well as secreted HBV DNA levels and intracellular HBV replication 
by affecting the autophagic degradative process. 
 
Figure 4.48 Activation of Rab7 inhibits HBV replication and HBsAg production 
Huh7 cells were cotransfected with pSM2 plasmid and Rab7 WT, Rab7 DN, or control vector pEGFP-N1 and 
harvested after 72 h. Analysis of encapsidated HBV DNA was performed by Southern blotting. (A) The levels of 
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secreted HBsAg and HBeAg in the supernatant and intracellular HBsAg from cell lysates were determined by 
chemiluminescent microparticle immunoassay. (B) The graph shows the relative values of HBsAg from the 
supernatant and cell lysates. (C) The levels of HBV genomes inside the cells were determined by quantitative 
real-time polymerase chain reaction. Analysis of HBV replicative intermediates was performed by Southern 
blotting. (D) The graph shows the relative values of intracellular viral genomes. S/CO = signal to cutoff ratio; 
RC: relaxed circular DNA; SS = single-stranded DNA. *, # P < 0.05; **, ## P < 0.01; ***, ### P < 0.001. 
 
4.5.7 Silencing of Rab7 promotes HBV production by interfering with autophagosome 
and lysosome fusion 
To investigate the detailed mechanism of modulation of HBV formation mediated by Rab7, 
we analyzed the effect of Rab7 on the autophagosome formation. Colocalization of GFP-LC3 
with HBs-Cherry was examined by confocal microscopy in Huh7 cells. We observed that 
silencing of Rab7 increased the number of GFP-LC3 puncta (Figure 4.41, A). Additional 
confocal microscopy results showed that silencing of Rab7 led to increase colocalization of 
GFP-LC3 with HBs-Cherry, showing a similar effect as CQ (Figure 4.49, A and B). These 
data indicate that blocking autophagic degradation caused by silencing of Rab7 leads to a 
decrease in intracellular HBsAg. 
Because autophagic cargo degradation is the final step, we mainly focused on lysosomal 
function or autophagosome-lysosome fusion resulting from silencing of Rab7. Previous 
reports showed that knockdown of Rab7 had no obvious effect on the degradation of formed 
autophagosomes, but impaired autophagosome-lysosome fusion. Thus, the colocalization of 
LAMP1 with HBs-Cherry was further analyzed. The colocalization coefficient was markedly 
decreased by silencing of Rab7, but markedly elevated by treatment with CQ (Figure 4.49, C 
and D). These results indicate that degradation of HBsAg results from impaired of 
autophagosome-lysosome fusion. 
Finally, after transfection with a specific siRab7 and siRNA control, the results were further 
confirmed by treatment with rapamycin, CQ, or 3-MA. Quantification of secreted HBsAg in 
the supernatant and intracellular HBsAg from cell lysates revealed that rapamycin further 
increased the levels of secreted and intracellular HBsAg with or without silencing of Rab7 in 
HepG2.2.15 cells (Figure 4.50). However, CQ did not further increase the levels of secreted 
and intracellular HBsAg after silencing of Rab7 compared to the siRNA control. Moreover, 
3-MA decreased the levels of secreted and intracellular HBsAg after silencing of Rab7, but 
the difference was not significant. Thus, these data strongly indicate that silencing of Rab7 
increases the levels of secreted and intracellular HBsAg by interfering with autophagosome 
and lysosome fusion.  
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Figure 4.49 Silencing of Rab7 decreases the interaction of lysosomes with HBsAg 
(A) Huh7 cells were transfected with HBsAg plasmid with expressing mCherry. At 24 h post-transfection, the 
cells were split and cotransfected with GFP-LC3 plasmid and specific siRab7 or control siRNA (siR-C) at 20 nM 
and harvested after 48 h. The cells were fixed and stained with DAPI (blue). The colocalization of LC3 (green) 
and HBsAg (red) was measured by confocal microscopy. Bars, 5 µm. (B) Statistical analysis of the 
colocalization coefficient of LC3 and HBsAg. (C) Huh7 cells were cotransfected with HBsAg plasmid with 
expressing mCherry and specific siRab7 or control siRNA (siR-C) at 20 nM and harvested at 48 h. The cells 
were incubated with anti-LAMP1, then stained with Alexa Fluor 488 - conjugated anti-rabbit secondary antibody 
IgG. The colocalization of LAMP1 (green) and HBsAg (Red) was measured by confocal microscopy. Bars, 5 µm. 
(D) Statistical analysis of the colocalization coefficient of LAMP1 and HBsAg. * P < 0.05; ** P < 0.01; *** P < 
0.001; ns, not significant. 
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Figure 4.50 Silencing of Rab7 increases HBV production by interfering with late autophagy 
HepG2.2.15 cells were transfected with specific siRab7 or control siRNA (siR-C) at 20 nM. At 24 h 
post-transfection, the cells were treated with 2 µM rapamycin (Rapa), 10 µM chloroquine (CQ), or 10 mM 3-MA 
for 48 h. The levels of secreted HBsAg and HBeAg in the supernatant and intracellular HBsAg from cell lysates 
were determined by chemiluminescent microparticle immunoassay. S/CO = signal to cutoff ratio. *, # P < 0.05; 
**, ## P < 0.01; ***, ### P < 0.001; ns, not significant. 
As shown in Figure 4.51, HBV was captured and segregated by autophagosome 
compartments, which are used for HBV replication and morphogenesis. Small GTPase Rab5 
participates in the earliest steps of autophagosome formation and is used for HBV replication 
and HBsAg production. Additionally, partial virus, including HBV capsid and HBsAg, are 
degraded by the fusion of autophagosomes and lysosomes. Another small GTPase Rab7 
controls the process of autophagosome with lysosome fusion. Thus, our findings suggest that 
HBV replication and HBsAg production require the early autophagic process, but will be 
degraded to a significant extent in the autophagosome compartments. 
 
 
Figure 4.51 Proposed model depicting different autophagic phases inversely modulate HBV replication 
A small GTPase, Rab5, participates in the earliest steps of autophagosome formation by providing various 
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membrane sources for the PAS through its interactions with the PIK3C3-BECN1 complex. HBV may be 
captured and segregated by autophagosome compartments, which are used for HBV replication and 
morphogenesis. Furthermore, HBV can exist in autophagosome compartments through certain mechanisms to 
evade degradation by lysosomes. Additionally, partial HBV may be degraded following the fusion of 
autophagosomes and lysosomes. Rab7 has different roles in the transport of autophagosomes and MVBs, 
particularly controlling the fusion process of autophagosomes with lysosomes. Thus, silencing of Rab7 led to 
accumulation of autophagosomes/MVBs and a subsequent increase in the amount of intracellular and released 
virus as a result of decreased viral transport to the lysosomes. 
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5 Discussion 
In the present study, we found that the miR-99 family members were able to promote HBV 
replication in hepatoma cells upon ectopic expression. All 3 members of the miR-99 family 
targeted components of the IGF-1R/PI3K/Akt/mTOR signaling pathway and negatively 
regulated this pathway. Among the downstream pathways under the control of the 
PI3K/Akt/mTOR signaling pathway, autophagy may play a major role in regulating HBV 
replication. Transfecting hepatocytes with miR-99 family members clearly promoted 
autophagy. Blocking the initiation of autophagy by 3-MA abolished the enhancing effect of 
the miR-99 family member on HBV replication. Based on the available data, we conclude that 
the miR-99 family promoted HBV replication via the IGF-1R/PI3K/Akt/mTOR/ULK1 
-autophagy axis. 
5.1 Low expression of mature miR-100 and miR-99a in hepatoma cells 
It is interesting that miR-99b is lowly expressed in PHHs, however, much more abundantly 
expressed than miR-100 and -99a in HepG2.2.15 cells. This observation could result from that 
fact that these 3 miRNAs are transcribed and supposedly regulated independently. The 3 
miR-99 family members are derived from different pri-miRNA transcripts. The locations of 
the coding sequences of miR-100, -99a, and -99b are on the Chromosome 11, NC_000011.10 
(122152229..122152308, complement), Chromosome 21, NC_000021.9 (16539089.. 
16539169) and Chromosome 19, NC_000019.10 (51692612..51692681), respectively. This 
explains why the level of miR-99b was increased while that of miR-99a and -100 decreased in 
hepatoma cells. While the level of miR-99b was increased in hepatoma cells, it did apparently 
not compensate the loss of miR-100 and -99a expression. Thus, ectopic expression of the 
miR-99 family members could target the cellular mRNAs with the corresponding seed 
sequence sharing by all the 3 miRNAs, finally with similar effect on the cellular gene 
expression and signaling as well as on HBV replication.  
 
5.2 The miR-99 family promotes HBV replication through mTOR/ULK1 signaling 
pathway-induced complete autophagy 
Data from several studies have demonstrated that HBV can promote the autophagy in 
hepatoma cells.87-89, 109, 150, 151 Sir et al. found that the HBx protein was able to bind to PI3KC3 
and enhance its enzymatic activity, an enzyme critical for the initiation of autophagy.87 The 
HBx was also found to upregulate Beclin1 expression and thereby sensitize cells to induce 
autophagy by starvation.150 Furthermore, Liu et al. showed that HBV- or HBx protein-induced 
autophagosome formation was accompanied by unchanged mTOR activity and decreased 
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degradation of autophagic cargo proteins.109 The HBx protein may prevent lysosomal 
acidification, in turn leading to reduced lysosomal degradative capacity and the accumulation 
of immature lysosomes, possibly through interaction with V-ATPase, affecting its lysosomal 
targeting. The repressive effect of HBx on lysosomal function inhibits autophagic degradation 
and may be linked to the development of HBV-associated HCC.109, 152 In addition, Li et al. 
showed that HBsAg was required for HBV-stimulated autophagy.89 
Autophagy was recognized to have a significant impact on HBV replication.87, 88, 130 
Independent research consistently demonstrated that autophagy inhibition strongly reduced 
HBV replication in hepatic cells.87, 89 Moreover, Tian et al. demonstrated that a deficiency in 
autophagy strongly reduced HBV replication in a transgenic mouse model.88 According to the 
available results, autophagy enhances HBV replication at the late stage, likely after at a step 
of capsid formation and viral assembly. Li et al. provided evidence that autophagy was 
required for HBV envelopment, although it was not necessary for HBV release.89 In 
agreement with previous reports, our results demonstrated that the miR-99 family positively 
regulated HBV replication at the post-transcriptional level. The regulation of HBV promoter 
activity was not affected by ectopic expression of miR-99 family members. The levels of 
HBV replicative intermediates, capsids, and secreted HBsAg/HBeAg in hepatoma cells 
markedly increased following the transfection of miR-99 family members. Early reports 
suggested that inhibition of the PI3K/Akt/mTOR signaling pathway could promote HBV 
transcription.80 In agreement with proposed mechanism, PI3K, Akt, and mTOR chemical 
inhibitors decreased the levels of phosphorylated Akt and mTOR protein expression in 
HepG2.2.15 cells. However, miR-99 family members decreased the levels of both total and 
phosphorylated IGF-1R, Akt, mTOR, and p70S6K protein expression but in a different extent 
compared to the chemical inhibitors. Our results suggest that miR-99 family members had 
likely milder inhibition on the IGF-1R/PI3K/Akt/mTOR signaling pathway than the chemical 
inhibitors. 
Bioinformatics analysis of HBV genomic sequences and testing with reporter plasmids 
suggested that miR-99 family members did not directly act on HBV mRNAs. Recent data 
have shown that cellular miRNAs have the potential to inhibit or stimulate viral replication in 
host cells by directly targeting the HBV genome or indirectly by targeting cellular genes.23, 27, 
153, 154 The miR-99 family has been shown to play an important role in many cellular and 
biological functions. MiR-99 family members were reported to target many cellular genes like 
IGF-1R, Akt, mTOR, Ago2, and several components of the TGF-β signaling pathway.155-157 
The regulation of these important cellular pathways by the miR-99 family was clearly 
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essential for controlling cell growth.136, 137 As shown previously, miR-99 family expression 
was reduced in primary human hepatocellular carcinoma, compared with that observed in 
matching normal liver tissues.137 We showed in the present study that miR-99 family 
members are expressed in PHHs and hepatoma cells. However, the expression levels of 
miR-99 family members in hepatoma cells were strongly reduced, compared with their 
expression levels in primary hepatocytes. Consequently, the dysregulation of cellular 
processes might decrease the ability of hepatocytes or hepatoma cells to support HBV 
replication. Consistent with this possibility, previous data showed that the loss of 
differentiation status of hepatocytes might greatly reduce the ability of cells to support HBV 
replication.23, 158, 159 Li et al. showed that replication of woodchuck hepatitis virus and viral 
antigen expression were gradually decreased in early pre-neoplastic cell line ages.160 In 
general, HBV replication is low or absent in HCC tissues, which are associated with the 
de-differentiation of hepatocytes. We demonstrated that the ectopic expression of miRNAs 
(like miR-1) in hepatoma cells could promote cell differentiation and restore, at least partially, 
the hepatocyte phenotype.23 
 
5.3 Different autophagic phases inversely affects HBV production 
As reported in previous studies, HBV is captured and segregated by the autophagosome 
/endosome compartments, which are used for HBV replication and morphogenesis.89, 161, 162 
Moreover, HBV can exist in autophagosome compartments through special mechanisms that 
help HBV evade degradation by lysosomes.89, 109 Thus, autophagy may be involved in 
different steps of the HBV life cycle.87-89 
The complete autophagic process mainly involves the formation of autophagosomes, 
known as early autophagy, and their fusion with lysosomes and cargo degradation in the 
lysosomes, known as late autophagy. We found that inhibition of different autophagic phases 
by chemical inhibitors led to opposite consequences on HBV replication and HBsAg 
production. Consistent with previous reports,109, 163 we found that the late autophagy inhibitor 
CQ increased the number of GFP-LC3 puncta in Huh7 cells as detected by 
immunofluorescence microscopy and the levels of autophagic cargo, LC3-II and p62, as 
shown by western blotting analysis in Huh7 cells. The main reason may be that CQ can block 
the autophagic degradation by inhibiting the lysosomal acidification.102, 109 As expected, 
another late autophagy inhibitor CID inactivated Rab7 to cause a similar effect on autophagy 
by disturbing autophagosome-lysosome fusion without inhibiting lysosomal acidification.149 
Thus, both late autophagy inhibitors significantly increased the amount of secreted and 
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intracellular HBsAg and the levels of HBV genomes in the supernatants and inside the cells. 
However, the early autophagy inhibitor 3-MA decreased the expression of LC3-II and 
increased p62 expression. 3-MA inhibited secreted and intracellular HBsAg and the HBV 
genomes.163 These data indicate that early autophagic flux is required for HBV production, 
and the late step is required for viral degradation. 
As endosomal Rab5 and Rab7 are related to the formation or degradation of early 
autophagic bodies and autophagosomes, they were evaluated in this study to determine their 
roles in HBV production. Because previous studies found that HBV infection strongly 
depended on Rab5 and Rab7 expression, HBV transport from early to mature endosomes may 
be a required step in the viral life cycle. Moreover, the well-known marker of EEs, Rab5, was 
reported to regulate the autophagosome formation by inhibiting mTOR kinase activity or by 
forming the complex interacting with Beclin1 and Vps34.114, 131 As the small GTPase Rab5 is 
related to the formation early autophagic bodies and autophagosomes, it is an excellent target 
to study their roles in HBV production. Our data showed that Rab5 was required for 
autophagosome formation in the early autophagy process, and it may serve as a critical 
regulator in HBV production. Previous studies showed that Rab5 was crucial for HCV 
replication, and thus it may have a similar function in an HBV-transfected hepatoma cell 
system. Consistent with our previous findings determined by silencing the components of the 
ULK1 complex or using the inhibitor 3-MA, HBV replication and HBsAg production were 
significantly decreased by silencing of Rab5. Furthermore, overexpression of mutant Rab5 
clearly decreased the levels of secreted and intracellular HBsAg and HBV DNA, while 
overexpression of constitutively active Rab5 was strongly increased. As previously reported, 
the mechanism may be that Rab5 controls the formation of autophagosomes by inhibiting 
mTOR kinase activity or by forming a complex that interacts with Beclin1 and Vps34. 
Regrettably, the detailed mechanisms of early autophagic phase to promote HBV 
replication or envelopment remain unknown.87 HBV envelopment is thought to occur at 
post-ER/pre-Golgi membranes, where cytosolic nucleocapsids are packaged inside a lipid 
envelope integrated with viral envelope proteins.162, 164-166 The following reasons may explain 
elevated HBV replication or envelopment in early autophagic phase. First, the autophagy 
pathway may enhance HBV replication or envelopment by sequestering the necessary 
restriction factor(s).102, 109 Moreover, autophagosomes provide a physical scaffold for HBV 
replication or envelopment.87, 163 Finally, autophagosome membranes may be as a source of 
membranes for viral envelopment. 89, 161, 162 
During the maturation process of EEs, inactivated Rab5 is substituted by Rab7 on the 
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endosomal membrane. Subsequently, Rab7 recruits its effectors, RILP and OSBPL1A/ORP1L, 
directs the LE trafficking, and participates in the fusion step with lysosomes.121, 167, 168 Thus, 
we hypothesized that HBV production is modulated by the late autophagic process mediated 
by Rab7. Our data revealed that silencing of Rab7 significantly enhanced HBV replication 
and HBsAg production. In contrast, activation of Rab7 clearly decreased the levels of HBV 
production. These data suggest that the delivery of viral capsids and HBsAg to lysosomes 
facilitate their degradation. Confocal microscopy revealed that degradation of HBsAg resulted 
from impaired autophagosome-lysosome fusion, followed by an increase in the levels of HBV 
replication and HBsAg production. 
In addition to Rabs, the vesicular transport and membrane fusion is also generally 
controlled by soluble N-ethylmaleimide-sensitive factor attachment protein receptors 
(SNAREs), including HOPS complex, STX17, SNAP29, and VAMP8.169 Previous studies 
showed that the tethering gene SNAP29 bridged lysosomal VAMP8 and autophagosomal 
Stx17 to mediate autophagosome-lysosome fusion.126 The phosphoprotein (P) of human 
parainfluenza virus type 3 (HPIV3) is necessary and sufficient to inhibition autophagosome 
degradation by binding to SNAP29 and inhibiting its interaction with syntaxin17. Thus, this 
thereby prevented the two host SNARE proteins from mediating autophagosome-lysome 
fusion, and resulted in increased virus production.170 To confirm the function of late 
autophagy, silencing or overexpression of the tethering genes, SNAP29 and VAMP8, showed 
a similar effect on HBV replication and HBsAg as Rab7 (Data not shown). This effect may be 
contributed to the critical function of tethering genes on autophagosome and lysosome fusion. 
Thus, our findings indicate that HBV replication and HBsAg production require early 
autophagic phase mediated by Rab5, but HBV is degraded to a significant extent in 
autophagosome compartments, which is mediated by Rab7.  
Taken together, our results demonstrated that the miR-99 family promotes HBV replication 
post-transcriptionally through IGF-1R/PI3K/Akt/mTOR/ULK1 signaling-induced complete 
autophagy. It suggests that more miRNAs may capable of facilitating HBV replication in 
hepatoma cells by promoting cell differentiation. Thus, the understanding of interactions 
between host miRNAs and HBV will continue to grow by incorporating new miRNAs and 
studying their new functions, which will potentially yield new insights of therapeutic 
relevance. 
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6 Summary 
In our present study, we investigated the influence of the miR-99 family members on HBV 
replication and gene expression. We found that ectopic expression of miR-99 family members 
could markedly increase HBV replication, progeny secretion, and antigen expression in 
hepatoma cells. However, miR-99 family members showed no effect on modulating HBV 
transcription and HBV promoter activities, suggesting that they may regulate HBV replication 
through other mechanisms. Consistent with bioinformatic analysis and recent reports, we 
further found that ectopic expression of miR-99 family attenuated IGF-1R/Akt/mTOR 
signaling pathway and repressed insulin-stimulated activation in hepatoma cells. Moreover, 
the experimental data revealed that the miR-99 family promoted the formation of 
autophagosomes through inhibiting the phosphorylation of ULK1, followed with the 
autophagic degradation of cargo receptor SQSTM1/p62. Thus, these results implied that the 
miR-99 family enhanced HBV replication through mTOR/ULK1 signaling induced complete 
autophagy. We further explored the definite mechanisms of different autophagic phases 
affecting HBV production. Consistent with our findings by silencing the components of 
ULK1 complex or using autophagic inhibitor 3-MA, HBV replication and HBsAg production 
were significantly decreased by silencing of Rab5. In contrast, silencing of Rab7 significantly 
enhanced HBV replication and HBsAg production, while activation of Rab7 obviously 
decreased the levels of HBV production. Thus, these data indicated that the delivery of HBV 
capsids and HBsAg to lysosomes could facilitate their degradation.  
Taken together, our results demonstrated that the miR-99 family promotes HBV replication 
post-transcriptionally through IGF-1R/PI3K/Akt/mTOR/ULK1 signaling-induced complete 
autophagy. We provide new evidence that HBV replication and HBsAg production requires 
early autophagic process, but may be degraded to a significant extent in the autophagosome 
compartment. 
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7 Zusammenfassung 
In der vorliegenden Arbeit wurde der Einfluss der miR-99 Familienmitglieder auf die 
Replikation des Hepatitis B Virus (HBV) und die virale Genexpression untersucht. Es konnte 
gezeigt werden, dass alle drei Mitglieder sowohl die HBV-Replikation, die Progenesekretion 
als auch die Antigenexpression in Hepatom-Zellen deutlich erhöhen. Die miR-99 Familie 
hatte jedoch weder Auswirkung auf die Transkription noch auf die Promotoraktivitäten von 
HBV. Dies lässt vermuten, dass die miR-99 Familienmitglieder die HBV-Replikation durch 
andere Mechanismen regulieren. Übereinstimmend mit bioinformatischen Analysen und 
jüngsten Publikationen konnte festgestellt werden, dass die ektopische Expression der miR-99 
Familie den IGF-1R/Akt/mTOR-Signalweg und die unterdrückte Insulin-stimulierte 
Aktivierung in Hepatom-Zellen abschwächte. Darüber hinaus zeigten die Daten, dass die 
miR-99 Familie die Bildung von Autophagosomen durch Hemmung der Phosphorylierung 
von ULK1 fördert und den Autophagie-vermittelten Abbau des Kargorezeptors SQSTM1/p62 
antreibt. Daraus lässt sich schließen, dass die miR-99 Familie die HBV-Replikation durch die 
vom mTOR/ULK1 Signalweg vollständig induzierte Autophagie verstärkte. Des Weiteren 
wurde untersucht, durch welchen Mechanismus die Produktion von HBV während der 
verschiedenen Phasen der Autophagie reguliert wird. Übereinstimmend mit vorherigen 
Ergebnissen wurde sowohl die HBV-Replikation und als auch die HBsAg-Produktion durch 
Silencing der Komponenten des ULK1-Komplexes oder unter Verwendung des 
autophagischen Inhibitors 3-MA signifikant durch die Degradation von Rab5 vermindert. Das 
Silencing von Rab7 hingegen steigerte die HBV-Replikation und die HBsAg-Produktion 
signifikant. Umgekehrt verringerte die Aktivierung von Rab7 offensichtlich  die Replikation 
von HBV. Daraus lässt sich schlussfolgern, dass die Abgabe von HBV-Kapsiden und HBsAg 
an Lysosomen ihren Abbau ermöglichen könnte. 
Die HBV-Replikation wird von der miR-99 Familie post-transkriptional via Autophagie 
gefördert, welche durch den IGF-1R/PI3K/Akt/mTOR/ULK1-Signalweg vollständig induziert 
wird. Die HBV-Replikation und die HBsAg-Produktion werden scheinbar durch einen frühen 
autophagischen Prozess gefördert. Ab einem bestimmten Niveau werden diese jedoch 
möglicherweise in den Autophagosomen abgebaut. 
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9 Abbreviations 
Abbreviations Full name 
3-MA 3-methyladenine 
CQ chloroquine 
3'-UTR 3'-untranslated region 
5'-UTR 5'-untranslated region 
cccDNA circular covalently closed DNA 
CHB chronic hepatitis B  
CMIA chemiluminescence immunoassay 
GFP green fluorescence protein 
DMEM Dulbecco’s Modified Eagles’s Medium 
DMSO dimethylsulfoxide 
DNA deoxyribonucleic acid 
E.coli Escherichia coli 
EEs early endosomes 
EDTA ethylenediaminetetraaceticacid 
ER endoplasmic reticulum 
FBS fetal bovine serum 
g gram 
HBcAg hepatitis B core antigen 
HBsAg hepatitis B surface antigen 
HBV hepatitis B virus 
HBV RI hepatitis B virus replicative intermediate 
HBx hepatitis B x antigen 
HCC hepatocellular carcinoma 
HCV hepatitis C virus 
HIV human immunodeficiency virus 
IFN interferon 
IGF1R insulin-like growth factor 1 receptor 
kb kilo base pair 
l liter 
LAMP1 lysosomal-associated membrane protein 1 
LEs late endosomes 
LC3 MAP1LC3, microtubule-associated protein 1 light chain 3 beta 
105 
 
LXRs liver X receptors 
m milli 
miRNA microRNA 
MEM Dulbecco’s Modified Eagle Medium 
min minute 
miRNAs microRNAs 
miR-C control microRNA 
mTOR  mammalian target of rapamycin 
SQSTM1/p62 sequestosome 1 
OSBPL1A/ORP1L oxysterol-binding protein-like 1A 
PBS phosphate buffered saline 
pCP  plasmid contains HBV core promoter region 
PCR polymerase chain reaction 
PCR polymerase chain reaction 
pgRNA pregenomic RNA 
pHBV 1 plasmid contains HBV fragment 1 
pHBV 2 plasmid contains HBV fragment 2 
pHBV 3 plasmid contains HBV fragment 3 
pHBV 3'UTR plasmid contains HBV 3'-termnal region 
pHBV FL  plasmid contains HBV full length genome 
PHH primary human hepatocyte 
PI3K  phosphatidylinositol 3-kinase 
RILP Rab-interacting lysosomal protein 
RT-PCR reverse transcriptase polymerase chain reaction 
SEM standard error of the mean 
siR-C control small interfering RNA 
siRNA small interfering RNA 
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